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Structure of the thesis 
II 
II STRUCTURE OF THE THESIS 
This thesis is structured into the main sections Introduction, Results and 
Summarizing discussion. The Introduction gives insights into the basic 
knowledge on brain astrocytes and microglial cells, on iron oxide and silver 
nanoparticles (IONPs and AgNPs) and the consequences of an exposure of glial 
cells to metal-containing nanoparticles. It also contains a recently published 
review article on handling of IONPs and AgNPs by astrocytes.  
The second part (Results) presents the results obtained during the work for 
this thesis. The results chapter is divided into three sub-chapters which 
contain two articles that describe the uptake of AgNPs by astrocytes and the 
biocompatibility of these particles. In addition a manuscript on the uptake of 
IONPs by microglial cells and on the intracellular localization of these particles 
is included which has been submitted for publication and is now in revision. 
The already published articles (chapter 1.5; chapter 2.1 and chapter 2.2) are 
embedded into this thesis as portable document format (pdf) in the style 
defined by the respective journal. The manuscript included as chapter 2.3 has 
very recently been reviewed and the suggestions made by the reviewers will be 
addressed in a revised version of this manuscript. As some additional 
experiments are required which, due to time constrains, cannot be performed 
before submission of this thesis, the initially submitted version of the 
manuscript has been included. The manuscript has been adapted to the 
general style of this thesis, but the text and the figures have not been altered. 
In this chapter the figures and tables are positioned with their legends 
between the results and the discussion part. 
The third part of the thesis presents the Summarizing discussion of the key 
experimental findings presented in this thesis. Furthermore it gives an outlook 
on future studies that are based on the work presented in this thesis.  
Figures and tables that are not included in the publications or manuscripts 
are labelled with the number of the respective main chapter followed by a 
running number according to their appearance in the text (for example, figure 
1.2 refers to the second figure in the first chapter).?
  
 
 
 
 
 
 
Summary 
III 
III SUMMARY 
Iron oxide nanoparticles (IONPs) and silver nanoparticles (AgNPs) are 
frequently used in everyday products as well as for biomedical applications. As 
nanoparticles (NPs) are known to cross the intact or damaged blood brain 
barrier, brain cells have to deal with NPs and NP-derived metal ions. 
Astrocytes and microglia are the first brain cells that are discussed to 
encounter NPs which reach the brain, but at the start of this thesis only little 
was known about the effects of AgNPs or IONPs on those cell types. 
The consequences of an exposure of astrocytes to AgNPs were studied on 
astrocyte-rich primary cultures as model systems. These cells efficiently took 
up AgNPs by endocytotic mechanisms and were neither acutely impaired in 
their viability nor during prolonged presence of accumulated AgNPs. Neither 
silver nor AgNPs was exported from the cells but presence of AgNPs in the cells 
was accompanied by an upregulation of metallothioneins that may safely store 
AgNP-derived silver ions, thereby protecting astrocytes against the potential 
toxicity of silver ions. These results are in line with the view that in brain 
astrocytes efficiently accumulate potentially toxic metals and metal-containing 
NPs and thereby provide protection for other brain cells. 
Primary microglial cultures were established and characterized as cell culture 
model of microglial cells and used to study the effects of an exposure of 
microglia to IONPs. Fluorescently labelled IONPs were applied to visualize the 
uptake and intracellular localization of IONPs. These NPs were rapidly taken 
up by microglia into lysosomal compartments via endocytotic mechanisms. 
Viable microglia appeared not to suffer from oxidative stress as the cellular 
glutathione levels remained stable, however, in contrast to astrocytes that had 
been treated with comparable IONPs, microglia only tolerated moderate 
concentrations of accumulated IONPs for a few hours before their viability was 
impaired which may be a consequence of a liberation of iron ions from the 
accumulated IONPs.  
The data presented in this thesis support the described differences regarding 
toxicity and uptake of NPs in astrocytes and microglia. This allows the 
assumption that astrocytes, due to their high capacity to take up NPs without 
impairment in their viability, may provide protection for microglial cells which 
efficiently accumulate NPs but are already damaged by the accumulation of 
relatively low concentrations. 
  
 
 
 
 
Zusammenfassung 
IV 
IV ZUSAMMENFASSUNG 
Eisenoxid- und Silber-Nanopartikel (IONPs und AgNPs) finden in Haushalts-
produkten und im medizinischen Bereich eine breite Anwendung. 
Nanopartikel (NPs) können die intakte oder geschädigte Blut-Hirn-Schranke 
überwinden und so mit Zellen des Gehirns in Kontakt kommen. Astrozyten 
und Mikroglia sind vermutlich die ersten Zelltypen, die auf ein NP-Vorkommen 
im Gehirn reagieren. Über Effekte von NPs auf diese Zelltypen war am Beginn 
dieser Arbeit jedoch nur wenig bekannt. 
Die Konsequenzen einer Exposition von Astrozyten gegenüber AgNPs wurden 
anhand von astrozytenreichen Primärkulturen untersucht. Diese Zellen 
akkumulierten große Mengen an AgNPs ohne akut oder durch anhaltende 
Präsenz von AgNPs in ihrer Vitalität beeinträchtigt zu sein. Das akkumulierte 
Silber wurde nicht exportiert, es konnte jedoch eine Hochregulation von 
Metallothioneinen beobachtet werden. Die Hochregulation dieser Speicher-
proteine gilt als Schutzmechanismus um das Gehirn vor möglichen Metall-
induzierten Schäden zu bewahren, was die These unterstützt, dass Astrozyten 
potentiell toxische Metalle akkumulieren um andere Zelltypen des Gehirns vor 
Schäden zu bewahren. 
Primäre Mikrogliakulturen wurden etabliert und charakterisiert um die Effekte 
einer Exposition von Mikroglia gegenüber IONPs zu untersuchen. Fluo-
reszierende IONPs ermöglichten die visuelle Darstellung akkumulierter NPs in 
den Zellen. Nach einer schnellen Aufnahme der IONPs über endozytotische 
Pfade wurden diese dem Abbau in Lysosomen zugeführt. Unter subtoxischen 
Bedingungen schienen die Zellen keinen oxidativen Stress zu erleiden, da 
keine Veränderung des zellulären Glutathiongehaltes festgestellt wurde. Im 
Gegensatz zu Astrozyten, die mit vergleichbaren IONPs inkubiert worden 
waren, konnten Mikroglia jedoch nur eine begrenzte Menge an akkumulierten 
IONPs tolerieren, bevor sie Schaden nahmen, was in der Freisetzung von 
Eisenionen aus den NPs begründet sein könnte.  
Die Daten dieser Doktorarbeit bestätigen die beschriebenen Unterschiede in 
Aufnahme und Toxizität von NPs in Mikroglia und Astrozyten. Dies lässt die 
Vermutung zu, dass Astrozyten durch ihre hohe Kapazität für die Aufnahme 
von NPs, ohne in ihrer Vitalität geschädigt zu werden, eine Schutzfunktion für 
Mikroglia ausüben könnten, die NPs zwar sehr effizient aufnehmen, aber 
bereits durch vergleichsweise geringe Konzentrationen geschädigt werden.  
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1.1 GLIAL CELLS 
The central nervous system (CNS) consists of different types of cells which can 
be classified into two major groups – excitable neurons and non-excitable glia 
cells. Neurons account for approximately 10% of the total cell number in the 
brain (Verkhratsky and Butt 2007). The remaining 90% are glial cells which 
are crucial for brain development and maintenance (Araque and Navarrete 
2010, Verkhratsky 2010, Kettenmann et al. 2011, Pellerin and Magistretti 
2012) and fulfil a number of important tasks, including structural and 
metabolic support, insulation of neurons, immune surveillance and guidance 
of development (Araque and Navarrete 2010, Sofroniew and Vinters 2010, 
Verkhratsky 2010, Kettenmann et al. 2011, Pellerin and Magistretti 2012). 
Glial cells can be sub-divided into microglia and macroglia.  
?
Figure 1.1: Schematic picture of the different brain cell types. Yellow: 
neuron; purple: oligodendrocyte; blue: astrocyte; green: microglia; red: 
blood capillary. 
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Microglia are the immune competent cells of the brain (Kettenmann et al. 
2011) while macroglia can be further divided into oligodendrocytes, astrocytes 
and ependymal cells. Oligodendrocytes build the myelin sheaths around 
neuronal axons to enable saltatory signal conduction along the axons (Miron 
et al. 2011), ependymal cells form the walls of brain ventricles (Verkhratsky 
and Butt 2007, Kishimoto and Sawamoto 2012) and astrocytes have a variety 
of structural and metabolic functions. This thesis particularly focuses on 
astrocytes and microglial cells that are introduced in detail below.   
1.1.1 ASTROCYTES 
Astrocytes are the most abundant cells type in brain (Araque and Navarrete 
2010) and outnumber neurons by five-fold (Sofroniew and Vinters 2010). 
Astrocytes were first described already in 1858 by Rudolf Virchow as tissue 
that binds together nervous elements (cited in Parpura et al. 2012), but these 
cells received their name “astrocytes” much later by Michael von Lenhossek in 
1891 (cited in Parpura et al. 2012). Although known for more than 100 years, 
astrocytes were deemed for a long time to be only supporting cells for neurons 
and intensive studies on glial cells emerged only in the last decades 
(Verkhratsky 2010, Parpura et al. 2012). Nowadays it is generally accepted 
that astroglial cells are much more than neuronal glue.  
1.1.1.1 Astrocytes during development 
Astrocytes are of ectodermal origin (Sofroniew and Vinters 2010), their 
differentiation occurs during the late embryonic and early postnatal period 
(Lee et al. 2009). This is in temporal coincidence with the formation of the 
blood brain barrier (BBB) where astrocytes are described to participate (Lee et 
al. 2009). In addition, astrocytes play a crucial role in brain architecture by 
shaping dendritic morphology (Korn et al. 2011) and forming structures which 
guide migrating neurons (Powell and Geller 1999, Verkhratsky and Butt 
2007). They are also essential for the formation (Faissner et al. 2010, Pfrieger 
2010), maintenance and elimination of synapses (Stevens 2008). However 
since synaptogenesis of GABAergic (GABA: gamma-aminobutyric acid) 
neurons takes place before astrocytes differentiate (Huang and Scheiffele 
2008), only the development of glutamatergic connections is considered to 
depend on astrocytes (Pfrieger 2010). 
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1.1.1.2 Astrocytes and brain architecture 
Astrocytes in the vertebrate brain form ten-thousands to millions of processes 
(Oberheim et al. 2009, Verkhratsky 2010). They play a crucial role in 
sustaining brain architecture as there is no region in the brain that is devoid 
of astrocytes (Sofroniew and Vinters 2010). Astrocytes divide the brain tissue 
into relatively independent structural units according to their functional 
territories which is known as “tiling” (Sofroniew and Vinters 2010, 
Verkhratsky 2010). These territories only overlap in the very distal tips of 
processes. Here gap junctions are formed between the cells by connexins and 
several astrocytes build a functional syncytium (Verkhratsky 2010, Giaume 
and Liu 2012) that allows the intercellular exchange of ions like Ca2+, Na+ or 
K+ and of small molecules with a molecular mass less than 1.2 kDa like 
adenosine triphosphate (ATP), glucose, glutathione (GSH) or messenger 
molecules (Theis and Giaume 2012). This astrocytic syncytium supports, for 
example, long distance energy substrate trafficking towards activated neurons 
(Parpura et al. 2012, Theis and Giaume 2012).  
1.1.1.3 Astrocytes and synaptic transmission 
Astrocytes have also been described to take part in synaptogenesis and 
synapse maintenance in the adult brain (Pfrieger 2010). A single astrocyte 
contacts several hundred dendrites and covers a large number of synapses of 
numerous neurons (Sofroniew and Vinters 2010, Parpura et al. 2012). 
Astrocytes are able to respond to neuronal changes in activity by the release of 
gliotransmitters like ATP, glutamate or GABA (Sofroniew and Vinters 2010) 
and they ensure undisturbed synaptic transmission by maintaining pH, ion 
and neurotransmitter homeostasis in the interstitial fluid (Sofroniew and 
Vinters 2010). Neuronal activity can also result in the mobilization of 
intracellular Ca2+ stores from the endoplasmatic reticulum (ER) (Nimmerjahn 
2009) and generation of a Ca2+-wave that is transmitted intra- and 
intercellularly (Cornell-Bell et al. 1990, Fiacco and McCarthy 2006, Agulhon et 
al. 2012). The released Ca2+ may reach even distant cells and serves as an 
intercellular signal (Perea and Araque 2005, Goldberg et al. 2010). 
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1.1.1.4 Metabolic support by astrocytes 
Astrocytes and neurons are metabolically coupled as described for several 
metabolic pathways. The theory of the astrocyte-neuron lactate shuttle is 
known for 16 years now (Magistretti and Pellerin 1996, Pellerin and Magistretti 
2012) and still under debate (Dienel 2012). According to this theory astrocytes 
metabolize glucose to lactate which they release. The lactate is then taken up 
by neurons where it serves as an energy substrate (Barros and Deitmer 2010, 
Kimelberg and Nedergaard 2010, Pellerin and Magistretti 2012). Additionally, 
astrocytes supply amino acid precursors for the neuronal synthesis of the 
antioxidant GSH (Dringen et al. 2000, Dringen and Hirrlinger 2003, 
Fernandez-Fernandez et al. 2012, Schmidt and Dringen 2012, Valdovinos-
Flores and Gonsebatt 2012) and take part in the modulation of synaptic 
transmission by the uptake and release of neurotransmitters like glutamate or 
GABA (Sofroniew and Vinters 2010; Öz et al. 2012; Yudkoff et al. 2012). With 
their endfeet astrocytes cover virtually all vascular surfaces (Parpura et al. 
2012). This enables bidirectional interactions including regulation of the blood 
flow by release of various mediators that increase or decrease blood vessel 
diameter (Takano et al. 2006, Iadecola and Nedergaard 2007, Sofroniew and 
Vinters 2010) and uptake of nutrients from the blood via the BBB (Sofroniew 
and Vinters 2010). Astrocytes are also the first cells that encounter all other 
substances that have crossed the BBB like drugs or toxins. They play an 
important role in the detoxification of xenobiotics (Schmidt and Dringen 2009, 
Schmidt and Dringen 2010) or reactive oxygen species (Dringen et al. 2005, 
Hirrlinger and Dringen 2010) and are involved in metal homeostasis in the 
brain (Tiffany-Castiglioni and Qian 2001, Dringen et al. 2007, Scheiber and 
Dringen 2013). 
1.1.1.5 Astrocytes and metals 
Astrocytes are described to play an important role in metal metabolism in the 
brain as they have a strategically important position between blood capillaries 
and other brain cells (Dringen et al. 2007). The brain contains potentially 
toxic levels of essential metals like iron (Fe), copper (Cu), manganese (Mn) 
or zinc (Zn) (Tiffany-Castiglioni et al. 2001) which have important functions 
in the normal brain metabolism, for example as co-factors for enzymatic 
reactions, in protein and lipid synthesis or in cell proliferation (Dringen et 
al. 2007, Lee and Koh 2010, Filipov and Dodd 2012, Scheiber and Dringen 
2013). Astrocytes have been shown to be able to accumulate and store 
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such metals to prevent other brain cells from metal derived toxicity 
(Tiffany-Castiglioni and Qian 2001, Hoepken et al. 2004, Scheiber et al. 
2010). The handling of Fe, Cu or Mn by astrocytes has been reviewed 
earlier (Tiffany-Castiglioni and Qian 2001, Dringen et al. 2007, Moos et al. 
2007, Tiffany-Castiglioni et al. 2011, Scheiber and Dringen 2013), but also 
other metals, that have no functions in normal brain metabolism like lead (Pb) 
or silver (Ag) can be taken up efficiently by astrocytes (Tiffany-Castiglioni and 
Qian 2001, White et al. 2007).  
Astrocytes possess machineries to increase their capacity to store potentially 
toxic metals by upregulation of metal storage proteins like ferritin (Ft) or 
metallothioneins (MTs) (Hidalgo et al. 1994, Kramer et al. 1996, Aschner et al. 
1998, Hoepken et al. 2004, Geppert et al. 2012). Such an upregulation allows 
these cells to withstand high metal excess without suffering from metal-
induced toxicity. 
1.1.2 MICROGLIA 
Microglial cells are the immune competent cells in the brain which were first 
described by Pio del Rio-Hortega in 1932 (cited in Kettenmann et al. 2011). 
These cells possess various properties of peripheral macrophages (Vilhardt 
2005). Microglia release neurotrophic factors and anti-inflammatory cytokines 
and promote synaptic plasticity (Czeh et al. 2011, Kettenmann et al. 2011, 
Schafer et al. 2012), but upon injury of the brain or immunological stimuli 
microglia become activated resulting in the production of pro-inflammatory 
proteins and reactive oxygen species (ROS) that may result in neuronal 
damage (Ransohoff and Perry 2009, Lull and Block 2010, Smith et al. 2012).  
1.1.2.1 Microglia in developing brain 
Microglia are of myeloid origin and migrate into the brain from bone marrow 
during development (Chan et al. 2007, Lull and Block 2010, Kettenmann et al. 
2011). First microglial progenitors occur in the head region of rat embryos 
already around embryonic day 11 – 14 (Sorokin et al. 1992, Pont-Lezica et al. 
2011). With proceeding brain development the number of early microglial cells 
increases. This is described to be linked to the occurrence of apoptotic cells 
(Pont-Lezica et al. 2011, Harry and Kraft 2012). In the developing brain, 
neurons form numerous synaptic connections from which only a subset is 
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maintained and strengthened with proceeding development (Stevens et al. 
2007, Pfrieger 2010, Schafer et al. 2012). Additionally, many neurons undergo 
apoptosis around the time of birth (Wakselman et al. 2008, Schlegelmilch et al. 
2011) and are shown to be phagocytosed by microglia which participate in the 
modulation of synapses (Schafer et al. 2012). In this stage microglial cells have 
an amoeboid morphology that facilitates their phagocytotic properties (Lull 
and Block 2010). After birth microglia become more ramified as they fully 
differentiate. This process is hypothesized to coincide with the maturation of 
neurons and glia cells (Pont-Lezica et al. 2011, Harry and Kraft 2012).  
1.1.2.2 Activation of microglia 
In healthy brain microglia are reported to be in a “resting” state with a 
ramified morphology. However, “resting” microglia are not inactive, but are 
constantly surveying their immediate surroundings (Kettenmann et al. 2011). 
Their membranes are equipped with a variety of receptors (Kettenmann et al. 
2011) which enable detection and classification of substances or particles in 
the extracellular space. Depending on the type of receptor activated, microglia 
respond differently in their downstream signalling. The response of microglia 
to such stimuli is referred to as “activation” which includes numerous states 
from moderate response to neurotoxic over-activation (Lull and Block 2010, 
Kettenmann et al. 2011). The cells undergo morphological changes from 
ramified to amoeboid which is believed to favour phagocytosis and motility 
(Lull and Block 2010). The presence of apoptotic cells or cell debris is 
recognized by the phosphatidylserine receptor leading to phagocytosis and 
simultaneous release of anti-inflammatory cytokines like transforming growth 
factor ? without any inflammation (Napoli and Neumann 2009). This process 
can be classified as mainly beneficial moderate activation. Many pathogens on 
the other hand express patterns that are recognized via toll-like receptors 
triggering the release of pro-inflammatory signals like tumour necrosis factor ? 
(TNF-?), interleukin 1? (IL-1?), nitric oxide (NO) or ROS (Napoli and Neumann 
2009, Lull and Block 2010). A third way described to regulate microglial 
response is the absence of signal. Constitutively expressed calming signals 
from surrounding cells carry information about normal neuronal activity. The 
release of neurotransmitters or the binding of proteins to respective receptors 
on microglial cells have an inhibitory effect on microglial activation (Bessis et 
al. 2007, Hanisch and Kettenmann 2007, Lull and Block 2010, Saijo and 
Glass 2011). Any impairment of neuronal integrity may lead to the disruption 
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of these signals, alerting microglia and subsequently resulting in their 
activation (Hanisch and Kettenmann 2007). This enables microglial cells to 
react to any unknown disturbance without activation of a specific receptor 
(Hanisch and Kettenmann 2007, Kettenmann et al. 2011). 
1.1.2.3 Microglia in disease 
Upon exposure to stress- or damage-signals from other cells, microglia become 
acutely activated to proliferate, migrate to these sites and work in a 
neuroprotective mode by releasing anti-inflammatory cyto- and chemokines 
(Graeber and Streit 2010). If the support provided by microglia is not sufficient 
and the damaged cells cannot be saved, microglia will clear up the debris by 
phagocytosis (Graeber and Streit 2010). If the activation signals from damaged 
cells are continuously released, microglia become chronically activated. In this 
state of over-activation, also termed “reactive microgliosis”, microglia 
continuously produce and release pro-inflammatory substances like TNF-? 
and IL-1? as well as ROS and NO which can damage surrounding neurons 
(Graeber and Streit 2010, Lull and Block 2010). Prolonged over-activation is 
described to lead to ageing and senescent microglia and subsequently to 
microglial degeneration (Graeber and Streit 2010). Therefore microglia seem to 
play both causative and amplifying roles in many neurodegenerative disorders 
(Lull and Block 2010) like Parkinson´s or Alzheimer´s disease (Saijo and Glass 
2011, Phani et al. 2012, Rubio-Perez and Morillas-Ruiz 2012), multiple 
sclerosis (MS) or HIV-associated neurocognitive disorder (Ransohoff and Perry 
2009, Saijo and Glass 2011) as well as in conditions like stroke (Thiel and 
Heiss 2011). 
1.1.2.4 Microglia and metals 
Disturbance of metal homoeostasis is often described to be associated with 
diseases like Alzheimer’s disease (Batista-Nascimento et al. 2012), MS 
(Williams et al. 2012) or Parkinson´s disease (Sian-Hülsmann et al. 2011, 
Mounsey and Teismann 2012) in which microglial activation is a common 
observation (Saijo and Glass 2011, Phani et al. 2012, Rubio-Perez and 
Morillas-Ruiz 2012). Therefore the effects of metals on brain cells have often 
been studied in the context of microglial activation (Zheng et al. 2010, Higashi 
et al. 2011, Rathnasamy et al. 2011, Filipov and Dodd 2012). Especially iron is 
essential for basic cellular processes like energy production or cell 
metabolism (Fretham et al. 2011). Iron excess, however, is dangerous and 
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can lead to cellular impairment and radical production via Fenton 
chemistry (Jomova et al. 2010). Iron deficiency as well as an excess of iron 
are connected with many diseases and mental impairments (Jomova et al. 
2010, Fretham et al. 2011, Rathnasamy et al. 2011, Batista-Nascimento et 
al. 2012). Therefore a strict regulation of the iron metabolism in brain is 
necessary.  
In the developing and early postnatal brain most iron is present in 
microglia (Connor et al. 1995, Schonberg and McTigue 2009) and activated 
microglia are described to contain Ft (Cheepsunthorn et al. 1998, Hoepken 
2005) and the transferrin receptor (TfR) (Kaur and Ling 1995, Hoepken 
2005). With maturation of the other glial cells and differentiation of 
microglia, the brain iron store is shifted from microglia towards 
oligodendrocytes which become the major iron-containing cells in brain 
(Connor et al. 1995) as many iron-dependent enzymes are required for 
myelination of axons (Connor and Menzies 1996). In their “resting” state 
microglia do contain only low amounts of iron and iron-related proteins 
(Moos 1995, Hoepken 2005, Moos et al. 2007).  
However, upon extracellular iron excess or activation, differentiated 
microglial can revive their ability to transport and store iron and are 
described to actively regulate iron homeostasis (Rathnasamy et al. 2011). 
In such conditions microglia contain proteins for iron uptake like the 
divalent metal transporter 1 (DMT1) (Rathore et al. 2012), melanotransferrin 
(Mtf) (Jefferies et al. 1996) or TfR (Kaur and Ling 1995, Rathnasamy et al. 
2011) as well as iron binding and storing proteins like Ft (Cheepsunthorn 
et al. 1998, Cheepsunthorn et al. 2001, Zhang et al. 2006) or lactoferrin 
(Lf) (Fillebeen et al. 2001, An et al. 2009) which the cells may release to 
supply surrounding cells with a redox-inactive form of iron (Fillebeen et al. 
2001, Zhang et al. 2006). Whether they also contain the iron exporter 
ferroportin (FPN) is still controversially discussed (Moos et al. 2007, 
Rathore et al. 2012).  
Figure 1.2 compiles the knowledge on pathways that are described to be 
involved in the iron metabolism in microglia during activation or in connection 
with diseases. However, it has to be stated, that some pathways are described 
for a single disease only. Mtf, for example, was detected in microglia in senile 
plaques in Alzheimer´s disease, while in other pathological tissues it was 
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not expressed (Jefferies et al. 1996). It also should be kept in mind that in the 
state of disease only a subset of microglia might be involved in iron-processing 
or -storing (Kaur and Ling 1995, Lopes et al. 2008). In addition to the 
pathways depicted in figure 1.2, cytokines or ROS produced during activation 
may influence the expression of iron influx and storage proteins like DMT1 
and Ft (Rathore et al. 2012). 
 
 
?
Figure 1.2: Pathways described to be involved in the iron metabolism in 
microglia upon extracellular iron excess. The depicted pathways have been 
described for one or more pathological conditions that are connected with iron 
excess. Activated microglia increase their cellular labile iron pool by taking up iron 
by transferrin-independent mechanisms via DMT1 or Mtf or bound to Tf via the 
transferrin receptor (TfR). Due to their phagocytotic properties microglia may also 
take up iron-containing debris from their surroundings. Excess of intracellular iron 
leads to the upregulation of iron binding proteins Ft and Lf, which help to safely 
store iron in a redox-inactive form, but also elevates cytokine and ROS production. 
Intracellular ROS may release iron from Ft. Whether ferroportin is expressed in 
microglia is still under debate, but they are described to release of Ft and Lf to 
supply other cells with a safe, redox-inactive form of iron.  
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1.2 NANOPARTICLES 
Nanoparticles (NPs) have been defined as particles that have a size of 1 to 
100 nm in two or three dimensions (Auffan et al. 2009). They can be divided 
into two main groups – naturally occurring and manufactured NPs. Even 
though naturally occurring nanoparticles like carbon black, clay minerals or 
silica have always been part of this world and nanoparticle with anthropogenic 
origin are almost as old as mankind itself (Peterson 2004, Oberdorster et al. 
2005, Suh et al. 2009, Wiesenthal et al. 2011), nanotechnology as a separate 
field of research is rather young (Suh et al. 2009). Since the late 1960s NPs are 
considered for medical applications in drug delivery or as vaccines, but NPs 
were initially considered to be “pharmaceutical curiosities with no or only 
extremely limited application” (Kreuter 2007). Towards the end of the 20th 
century this view changed completely and nanotechnology is now considered 
as the emerging technology of the 21st century (Mangematin and Walsh 2012) 
and is expected to become a US$ 2.5 trillion market by 2015 (Invernizzi 2011).  
NPs can consist of various core materials like carbon, organic polymers, 
metals or metal oxides (Suh et al. 2009, Ai et al. 2011, Peralta-Videa et al. 
2011) and are often covered with a coat to stabilize them in the environment 
they are designed for (Fatisson et al. 2012). Frequently used coating materials 
are inorganic and organic molecules, polymers or proteins (table 1.2; chapter 
1.5, table 2).  
The small size and huge surface to volume ratio give NPs physical and 
chemical properties that differ from the respective bulk material (Auffan et al. 
2009, Behari 2010), which opens new fields of research and application for 
already known materials. For example, carbon nanotubes (CNTs) display 
special properties regarding elasticity and strength as well as electrical 
conductivity, what makes them an interesting tool for development of ultra 
strong fibers or biosensors (Lu et al. 2012). Quantum dots (QDs) are frequently 
used for visualization of cell tissue (table 1.2) due to their optical properties. 
Polymer NPs serve as vehicles for drug delivery (Elsabahy and Wooley 2012). 
Among the different types of NPs, silver nanoparticles (AgNPs) and iron oxide 
nanoparticles (IONPs) are of special interest, because AgNPs have 
antimicrobial properties and are already widely used in consumer products 
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(Wijnhoven et al. 2009, Ahamed et al. 2010, Dastjerdi and Montazer 2010, 
Tolaymat et al. 2010, Schluesener and Schluesener 2013) and IONPs are 
considered for a variety of medical applications (Weinstein et al. 2010, Kievit 
and Zhang 2011, Maier-Hauff et al. 2011). Therefore these two types of 
particles are introduced further in the following sections. 
1.2.1 SILVER NANOPARTICLES 
On the world markets the number of products containing nanomaterials has 
risen immensely during the last years. The “Project on Emerging 
Nanotechnologies”, a data base established by the Woodrow Wilson 
International Center for Scholars and the Pew Charitable Trusts in 2005 
(http://www.nanotechproject.org/), registered an increase in manufacturer-
identified nano-consumer products within 5 years by over 500% from 212 to 
1317 products in March 2011. Silver is by far the most frequently used 
material in nano-consumer products due to the potent antimicrobial 
properties and a relatively low toxic potential of AgNPs towards mammalian 
cells (Chen and Schluesener 2008, Dastjerdi and Montazer 2010).  
In March 2011, 313 consumer products containing AgNPs were registered in 
the projects database of which some examples are shown in figure 1.3. The 
large number of products containing AgNPs makes human exposure to AgNPs 
in everyday life very likely. As AgNPs are reported to enter the brain via the 
olfactory epithelium (Aschner 2009) or by causing inflammation or disruption 
of the BBB (Tang et al. 2008, Sharma et al. 2010a, Sharma et al. 2010b, Tang 
et al. 2010), it is highly likely, that the frequent exposure to AgNPs from 
consumer products leads to an accumulation of AgNPs in the body and 
subsequently in the brain. The consequences of an exposure of brain cells to 
AgNPs are a main topic of this thesis. 
The antimicrobial properties of AgNPs arise from a slow release of silver ions 
(Ag+) (Xiu et al. 2012, Schluesener and Schluesener 2013), which makes 
AgNPs much more effective than low molecular weight silver. Silver applied as 
silver salt dissolves quickly in the surrounding media and is bound by various 
substances including phosphate, chloride, sulphide or organic acids (Choi et 
al. 2009, Xiu et al. 2011) which reduce the bioavailability of Ag+ before 
reaching the intended site of action (Xiu et al. 2012). 
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In AgNPs the rate of Ag+ released from the particles is influenced by many 
factors (Chernousova and Epple 2013) like the particle size (Morones et al. 
2005, Paná?ek et al. 2006, Carlson et al. 2008, Sotiriou and Pratsinis 2010), 
surface charge (El Badawy et al. 2010), shape (Pal et al. 2007) or coating (Yang 
et al. 2011). Therefore, AgNP-toxicity can be indirectly influenced by varying 
these parameters. AgNPs display a potent antimicrobial tool, whose properties 
can be individually designed to meet specific requirements in the intended 
products. 
1.2.2 IRON OXIDE NANOPARTICLES 
IONPs are used in a much lower scale in consumer products compared to 
AgNPs, but IONPs are qualitatively important as potent tools in medicine 
(Weinstein et al. 2010, Kievit and Zhang 2011, Maier-Hauff et al. 2011). Due to 
their high relaxivity IONPs are in clinical use as contrast agents for magnetic 
resonance imaging (MRI). Several products containing IONPs like Resovist® or 
?
Figure 1.3: Consumer products containing silver nanoparticles. Depicted are 
examples for products that are described to contain nano-silver. Picture credits can 
be found in table 1.3 at the end of the reference section. 
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Endorem®/Feridex® have been approved by the United States Food and Drug 
Administration (FDA) for clinical application (Soenen and De Cuyper 2010). 
Those products are used as contrast agent for MRI in liver or spleen (Reimer 
and Vosshenrich 2004, Matuszewski et al. 2007, Soenen and De Cuyper 2010) 
but IONPs are also considered for an application in brain (Weinstein et al. 
2010, Xie et al. 2011). In cancer treatment IONPs can be utilized to outline 
tumours for precise surgery (Trehin et al. 2006) or for hyperthermia to destroy 
tumour tissue in an alternating magnetic field (Maier-Hauff et al. 2011). Due 
to their magnetic properties they are also considered as a tool for targeted 
drug delivery (Veiseh et al. 2010, Weinstein et al. 2010). These applications of 
IONPs are also interesting for a use in the brain. In hyperthermia, IONPs could 
be administered directly to the brain by injection into the tumour tissue 
(Giustini et al. 2011), but mostly IONPs are injected in the periphery and have 
to cross the BBB to reach the brain. In various animal studies the presence of 
IONPs in brain after peripheral administration of the particles has been shown 
(table 1.1) indicating that IONPs cross the intact BBB. More information on 
the synthesis and the properties of IONPs is given in chapter 1.5. 
1.2.3 EFFECTS OF METAL-CONTAINING NANOPARTICLES ON GLIAL CELLS 
Metal-containing NPs have been detected in brain upon peripheral application 
via different routes of exopsure by many research groups (table 1.1). They were 
shown to enter the brain by crossing or disrupting the BBB (Tysiak et al. 
2009, Sharma et al. 2010a, Tang et al. 2010) or via the olfactory epithelium 
(Aschner 2009) and will therefore come in contact with glial cells. Uptake of 
different NPs has been shown for all glial cell types (Calvo et al. 2001, Pickard 
and Chari 2010, Geppert et al. 2011, Jenkins et al. 2011), but the following 
sections will focus only on the effects of NPs on astrocytes and microglial cells 
as those cell types are main subjects of this thesis.  
A detailed description on the handling of NPs by astrocytes will not be given in 
this paragraph, since chapter 1.5 of this thesis represents a very recent and 
comprehensive review article on this topic. Therefore, the reader is referred to 
this article for an up to date overview on the consequences of a treatment of 
astrocytes with NPs as well as on the uptake and the metabolism of NPs in 
astrocytes.  
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Table 1.1: Selected studies in which NPs were detected in brain after 
application via different routes of exposure 
Nanoparticle Route of exposure References 
IONPs Injection into the brain Wang et al. (2011a) 
 Intravenous injection Trehin et al. (2006), 
  Rausch et al. (2002), 
  Xie et al. (2011), 
  Beckmann et al. (2011) 
 Intraperitoneal injection Alison et al. (2010) 
 Subcutaneous injection Oude Engberink et al. (2010) 
 Intragastric injection Wang et al. (2010)  
 Intranasal Wang et al. (2011b), 
  Wu et al. (2013) 
 ? Fleige et al. (2001) 
AgNPs Intravenous injection Dziendzikowska et al. (2012), 
  Sharma et al. (2010a), 
  Tysiak et al. (2009) 
 Subcutaneous injection Tang et al. (2008), 
  Tang et al. (2009) 
 Oral Loeschner et al. (2011), 
  van der Zande et al. (2012), 
  Hadrup et al. (2012) 
 Intranasal Genter et al. (2012), 
  Liu et al. (2012) 
AuNPs Intraperitoneal injection Lasagna-Reeves et al. (2010) 
AlNPs Intravenous injection Sharma et al. (2010a) 
CuNPs Intravenous injection Sharma et al. (2010a) 
CuONPs Intraperitoneal injection An et al. (2012) 
AuNPs: gold nanoparticles; AlNPs: alumina nanoaprticles; CuNPs: copper 
nanoaprticles; CuONPs: copper oxide nanoaprticle; ?: no information given  
 
Microglia have been frequently reported to be affected by metal-containing NPs 
in vivo and in vitro (table 1.2). Depending on the core and coating material and 
the test system used, the consequences of an exposure of microglial cells to 
those NPs differ strongly. Microglial exposure to IONPs and QDs has been 
studied by several groups, but little is currently known on the effects of an 
exposure of microglial cells to other types of metal-containing NPs. Only a few 
studies have described the effects of alumina-, gold- or titanium dioxide-NPs 
(AlNPs, AuNPs and TiO2NPs, respectively). A list of articles describing the 
effects of metal-containing NPs on microglia is given in table 1.2. 
  
Table 1.2: Literature describing the current knowledge on effects of metal-containing NPs on microglial cells. 
N9, N11, BV-2: microglial cell lines; IgG: immune globulin G; n/a: not available; PVA: polyvinyl alcohol.  
In
tro
d
u
c
tio
n
 
NP core NP coating Microglial 
cells 
Consequences on microglia References 
Iron oxide Dextran In vivo Co-localization with activated cells, labelling of 
microglia 
Rausch et al. (2002) 
Iron oxide Dextran-Cy5.5 In vivo Uptake in activated cells, labelling of microglia, 
outlining of brain tumours  
Trehin et al. (2006) 
Iron oxide Dextran-goat anti 
mouse IgG 
In vivo No enhanced activation compared to control Raju et al. (2011) 
Iron oxide Citrate In vivo Uptake into vesicular structures, labelling of 
microglia 
Tysiak et al. (2009) 
Iron oxide Polysaccharide with 
lipophilic green 
fluorescent dye  
Mixed 
primary 
culture 
Effective uptake into vesicular structures Pinkernelle et al. (2012) 
Iron oxide n/a In vivo, 
BV-2 
Phagocytotic uptake into vesicles, proliferation, 
activation, release of ROS and NO 
Wang et al. (2011b) 
Iron oxide  n/a BV-2 Uptake into endosomes Rosenberg et al. (2012) 
Iron oxide Dextran-fluorescein In vivo, 
secondary 
culture 
Time- and concentration-dependent uptake into 
vesicular structures, labelling of microglia, 
outlining of brain tumours, toxic effects in high 
concentrations 
Fleige et al. (2001) 
Iron oxide Dextran, aminoPVA 
+/- Cy3.5 
N9, N11 Time- and concentration-dependent uptake, 
enhanced in activated cells 
Cengelli et al. (2006) 
Polystyrene
-iron oxide 
Carboxyl-modified 
with fluorophor 
Nile Red 
Secondary 
culture 
Time-, concentration- and temperature-dependent 
uptake, toxic effects in high concentrations 
Pickard and Chari (2010) 
2
2
 
  
Table 1.2 continued: Literature describing the current knowledge on effects of metal-containing NPs on microglial cells. 
N9, BV-2: microglial cell lines, PEG: Poly(ethylene glycol), LPS: Lipopolysaccharide, TLR2: Toll-Like receptor 2, CD68: cluster of 
differentiation 68 (lysosomal membrane protein), BSA: Bovine serum albumin, TNF?: Tumour necrosis factor ?, NF-?B: Nuclear 
factor ?B, CTAB: cetyl trimethylammonium bromide; n/a: not available. 
In
tro
d
u
c
tio
n
 
NP core NP coating Microglial 
cells 
Consequences on microglia References 
QD Amino/PEG In vivo Uptake in activated cells, labelling of microglia, 
outlining of brain tumours 
Jackson et al. (2007) 
QD ZnS with LPS  
surface 
In vivo, 
N9 
Activation, formation of lipid droplets, enhanced 
expression of TLR2 and CD68, NO release 
Lalancette-Hebert et al. (2010) 
QD None or BSA N9 Uptake, size-dependent cellular localization and 
toxicity 
Lovric et al. (2005) 
QD Streptavidin In vivo, 
primary 
culture 
Uptake via receptor-binding and clathrin-mediated 
endocytosis, no release of cytokines 
Minami et al. (2012) 
QD Bound to 
amiloride-? peptide 
Primary 
culture 
Time-dependent uptake into lysosomes Tokuraku et al. (2009) 
TiO2 None In vivo, 
BV-2 
Activation, increased expression of TNF? and NF-
?B in activated microglia 
Shin et al. (2010) 
TiO2 None BV-2 ROS production Long (2006) 
AlNP n/a In vivo Activation Li et al. (2009) 
AuNP PEG or CTAB In vivo, 
N9 
Shape-dependent uptake and activation pattern, 
co-localization with lysosomal compartments, 
enhanced expression of TLR2, cytokine release 
Hutter et al. (2010) 
2
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Most of the applied types of NPs seem to trigger activation processes in 
microglia. The peripheral administration of AlNPs led to an increase in the 
number of activated microglial cells 60 days after the treatment in vivo (Li et 
al. 2009). Upon treatment with AuNPs, a transient activation of microglia in 
vivo and in the cell line N9 was shown, which strongly depended on shape and 
surface structure of the NPs (Hutter et al. 2010). Upon microglial exposure to 
TiO2NPs activation of the cells, increased expression of TNF-? and the nuclear 
factor ?B (NF?B) as well as ROS production have been reported (Long 2006, 
Shin et al. 2010). For QDs and IONPs contradictory results were found 
regarding the activation of cells. Raju et al. (2011) and Minami et al. (2012) 
report no enhanced activation and no release of cytokines upon IONP and QD 
exposure, respectively. In contrast, Wang and co-workers showed activation 
and release of ROS and NO after IONP treatment (Wang et al. 2011b) and 
Lalancette-Herbert et al. (2010) described activation and NO release upon QD 
exposure.  
Uptake of NPs into microglia has been shown for AuNPs (Hutter et al. 2010), 
QDs (Lovric et al. 2005, Jackson et al. 2007, Tokuraku et al. 2009, Lalancette-
Herbert et al. 2010, Minami et al. 2012) and IONPs (Fleige et al. 2001, Trehin 
et al. 2006, Tysiak et al. 2009, Pickard and Chari 2010, Wang et al. 2011b, 
Pinkernelle et al. 2012, Rosenberg et al. 2012). In addition, detailed time- and 
concentration-dependent uptake of IONPs and QDs into vesicular or lysosomal 
compartments has been described in several reports (Fleige et al. 2001, 
Tokuraku et al. 2009, Tysiak et al. 2009, Wang et al. 2011b, Minami et al. 
2012, Pinkernelle et al. 2012, Rosenberg et al. 2012). This uptake involves 
most likely endocytotic and/or phagocytotic processes (Wang et al. 2011b, 
Minami et al. 2012) which are also described for the uptake of IONPs into 
peripheral macrophages or macrophage cell lines (Gu et al. 2011, Lunov et al. 
2011). As especially activated microglial cells are described to efficiently take 
up QDs and IONPs (Rausch et al. 2002, Trehin et al. 2006, Jackson et al. 
2007), these cells can be selectively labelled by IONPs and QDs. Thus, such 
NPs display potent tools for drug delivery into brain tumours or for marking 
tumour outlines by using fluorescence-labelled particles or MRI techniques 
(Fleige et al. 2001, Rausch et al. 2002, Trehin et al. 2006, Jackson et al. 2007). 
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1.3 Aim of the thesis 
This thesis investigates the uptake and metabolism of AgNPs and IONPs into 
cultured brain astrocytes and microglia. Due to their location and key 
functions in brain (Sofroniew and Vinters 2010, Kettenmann et al. 2011), 
these glial cells are especially prone to nanoparticle contact (Pickard and Chari 
2010, Geppert et al. 2011) and are considered as first lines of defence against 
metal stress in the brain (Oshiro et al. 2008) that may originate from NPs. 
This thesis will describe the consequences of an exposure of cultured 
astrocytes to AgNPs. The molecular mechanisms involved in AgNP uptake as 
well as potential alterations of metabolism after exposure to AgNPs will be 
studied. Furthermore, the consequences of a long term presence of AgNPs in 
astrocytes will be investigated. 
A second experimental part of this thesis will deal with cultured microglial 
cells and how they respond to an exposure to fluorescent IONPs. Primary 
microglial cultures will be established and characterized. These cultures will 
be exposed to fluorescent IONPs and the accumulation of iron in the cells and 
the involved uptake mechanisms will be studied. The fluorescence of the 
IONPs will be used as tool to localize the particles within the cells.  
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Table 1.3: Picture credits for figure 1.3. All web references were last 
accessed on 2013/02/04. 
Product 
class 
Web reference  
Medical 
products 
• http://www.bmbf.de/pub/nanoparticles_small_things_big_effe
cts.pdf 
• http://www.modernmedicine.com/news/acs-silver-delivery-
system-promotes-wound-healing  
Spray • http://www.nanogist.com/English/products/spray.htm 
Personal 
hygiene 
• http://lktrading.en.ec21.com/Toothbrush--2298648.html 
• http://lktrading.en.ec21.com/Oragan_Nano_SIlver_Toothpaste
--2553324_2298958.html 
Cosmetics • http://www.healthcare-
exp.com/b2b/pharmaceutical_chemicals/1/ 
Food 
packaging 
• http://www.alwaysfreshstoragecontainers.com 
Textiles • http://www.nanotechproject.org/inventories/consumer/brows
e/products/5121/ 
• http://bjsocks.e.tradeee.com/product_view/51177103/Nano-
Silver Socks with Foot Support and Half Cushion.html 
Electrical 
equipment 
• shop.12v-kuehlgeraete.de/ 
• http://www.washingmachineproblems.advicev.com 
• http://www.nanotechproject.org/inventories/consumer/brows
e/products/7218/ 
Paint • http://www.scientificamerican.com/article.cfm?id=silver-
coating-fights-microbes Picture by Luis Carlos, iStockphoto 
• http://www.remmers.de/Schimmel-Protect.1718.0.html#bot 
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Abstract 
Microglia are the phagocytotic cells of the brain that rapidly respond to 
alterations in brain homeostasis. Since iron oxide nanoparticles (IONPs) are 
used for diagnostic and therapeutic applications in the brain, the 
consequences of an exposure of microglial cells to IONPs are of particular 
interest. To address this topic we have synthesized and characterized 
fluorescent BODIPY®-labelled IONPs (BP-IONPs). The average hydrodynamic 
diameter and the ?-potential of BP-IONPs in water were about 65 nm and -
49 mV, respectively. Both values increased after dispersion of the particles in 
serum containing incubation medium to around 130 nm and -8 mV. Exposure 
of cultured rat microglial cells with BP-IONPs caused a time-, concentration- 
and temperature-dependent uptake of the particles as demonstrated by strong 
increases in cellular iron contents and cellular fluorescence. Incubation for 
3 h with 150 µM and 450 µM iron as BP-IONPs increased the cellular iron 
content from a low basal level of around 50 nmol iron/mg to 219 ± 52 and 
481 ± 28 nmol iron/mg protein, respectively. These conditions did not affect 
cell viability, but exposure to higher concentrations of BP-IONPs or for longer 
incubation periods severely compromised cell viability. The BP-IONP 
fluorescence in viable microglial cells was co-localized with lysosomes. In 
addition, BP-IONP accumulation was lowered by 60% in the presence of the 
endocytosis inhibitors 5-(N-ethyl-N-isopropyl)amiloride, tyrphostin 23 and 
chlorpromazin. These results suggest that the rapid accumulation of BP-IONPs 
by microglial cells is predominantly mediated by macropinocytosis and 
clathrin-mediated endocytosis which direct the accumulated particles into the 
lysosomal compartment. 
 
 
Key words: endocytosis; iron; lysosomes; microglia; nanoparticles; transport 
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1. Introduction  
Iron oxide nanoparticles (IONPs) are used for neurobiological applications 
including cancer treatment by hypothermia, as contrast agents for magnetic 
resonance imaging (MRI) as well as for targeted drug delivery and cell 
transfection [1, 2]. Direct access of IONPs to brain tissue is achieved by 
injection into the affected brain area for treatment of brain tumours [3]. 
However, also IONPs that are administered peripherally by oral application, 
intravenous injection or by inhalation have been reported to enter the brain by 
crossing the blood brain barrier or via the olfactory system [1, 2, 4-6].  
Microglial cells are the immune competent cells of the brain. Depending on the 
situation, microglial cells can act beneficial or harmful to their neighbouring 
cells. In the healthy adult brain, so-called “resting” microglia survey their 
microenvironment for nutrients or debris, release neurotrophic factors and 
anti-inflammatory cytokines and promote synaptic plasticity [7, 8]. However, 
upon activation by brain injury or infections, microglial cells migrate to the 
site of the impact and secrete inflammatory proteins and reactive oxygen 
species (ROS) that may damage neighbouring cells [7, 9]. Microglial cells will 
encounter nanoparticles that have entered the brain, since these cells are 
known to literally scan their surroundings for debris and particles which are 
subsequently taken up [7-9]. Indeed, exposure of animals with IONPs as 
contrast agents for MRI revealed that in brain especially the microglial cells 
are strongly labelled [10-13].  
Metal containing nanoparticles (NP) such as IONPs, titan dioxide NPs, gold 
NPs, alumina NPs or quantum dots have been reported to affect microglial 
functions in vivo and have been connected with cell toxicity, microglial 
activation, production of ROS and cytokine release [10-18]. However, so far 
little information is available on the mechanisms involved in the uptake of 
IONPs by microglial cells. A few studies have used microglial cell lines as 
model systems to gain information on the consequences of an exposure of 
microglial cells with IONPs [12, 19-21]. However, it has to be considered that 
the advantageous feature of immortality of cell lines may be accompanied by 
properties and behaviours that differ to those of primary cells [8, 22].  
Cells in secondary microglial cultures have been shown to accumulate 
fluorescent IONPs by analysis of their cellular fluorescence [13, 23]. However, 
a detailed quantitative analysis of IONP uptake into microglial cells as well as 
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an identification of mechanisms involved in particle uptake have to our 
knowledge not been reported so far. To address such questions we have 
synthesized and characterized fluorescent BODIPY®-labelled IONPs (BP-IONPs) 
that were subsequently used to investigate IONP uptake into cultured primary 
microglial cells. These cells efficiently accumulated BP-IONPs in a time-, 
concentration- and temperature-dependent manner by endocytotic processes 
which direct the accumulated particles into the lysosomal compartment. 
2. Materials and Methods  
2.1. Materials  
Fetal calf serum (FCS), trypsin solution and penicillin/streptomycin solution 
were obtained from Biochrom (Berlin, Germany). Dulbecco´s modified Eagle´s 
medium (DMEM) was from Gibco (Karlsruhe, Germany) and 4-(2-
hydroxyethyl)-1-piperazine ethanesulfonic acid (HEPES) from Roth (Karlsruhe, 
Germany). Bovine serum albumin and NADH were from Applichem 
(Darmstadt, Germany). BODIPY® FL C1-IA [N-(4,4-difluoro-5,7-dimethyl-4-
bora-3a,4a-diaza-s-indacene-3-yl)methyl) iodoacetamide] and lysotracker Red 
DND-99 were purchased from Invitrogen (Darmstadt, Germany). 5-(N-ethyl-N-
isopropyl)amiloride (EIPA), tyrphostin 23, ferrozine, dimercaptosuccinic acid 
(DMSA), 4´,6-diamidino-2-phenylindol hydrochloride (DAPI) and 
paraformaldehyde were purchased from Sigma-Aldrich (Steinheim, Germany). 
Mouse anti-rat CD11b (Ox-42) antibody was purchased from Serotec 
(Düsseldorf, Germany) and the Cy3-conjugated anti-mouse immunoglobulin 
from Dianova (Hamburg, Germany). Other chemicals of the highest purity 
available were purchased from Fluka (Buchs, Switzerland) or Merck 
(Darmstadt, Germany). 96-well microtiter plates and 6-well cell culture plates 
were from Nunc (Wiesbaden, Germany) and 24-well cell culture plates from 
Sarstedt (Nümbrecht, Germany). 
2.2. Synthesis and characterization of BP-IONP  
IONPs were synthesized by chemical co-precipitation of ferrous and ferric iron 
salts as described previously [24]. The nanoparticles were coated with 
BODIPY® (BP)-labelled DMSA according to a modification [25] of a published 
method [26]. BP-DMSA was synthesized by thoroughly mixing 712.5 µM 
BODIPY® FL C1-IA and 4.75 mM DMSA in 47.5 mM glycine/NaOH buffer 
(pH 10). A 30 min incubation at room temperature (RT) led to the complete 
derivatization of BODIPY® FL C1-IA with thiol groups of DMSA (data not 
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shown). Electrospray ionization mass spectrometry revealed the expected 
signals at 470 m/z and 759 m/z for DMSA labelled with BP on one or both 
thiol groups, respectively (data not shown). IONPs were added to the BP-DMSA 
reaction mixture to a final concentration of 21.4 mM and the mixture was 
acidified to pH 3 by concentrated HNO3. After mixing for 30 min at RT, the 
particles were separated from the solution by magnetic force, resuspended in 
H2O and redispersed by increasing the pH value with NaOH to pH 9-10. 
Finally, the pH was lowered to 7.4 by adding HCl. This dispersion was diluted 
with water to a final iron concentration of 40 mM and stored at 4°C. The 
concentrations of BP-IONPs used in the individual experiments are given here 
as concentration of the iron present in the nanoparticle dispersion and do not 
represent the concentration of particles.  
Samples for transmission electron microscopy (TEM) were prepared by 
dropping 5 µL of 1 mM BP-IONP dispersion in water onto carbon-coated 
copper grids and subsequent air drying at RT. Images were taken by a FEI 
Tecnai F20 S-TWIN (Hillsboro, Oregon, USA) operated at 200 kV equipped with 
a GATAN GIF2001 SSC-CCD camera. Energy dispersive X-ray analysis (EDX) 
was used for elemental analysis in the scanning mode of the microscope 
(STEM) with an EDAX r-TEM-EDX-detector with an energy resolution of 
136 eV. The hydrodynamic diameters and the ?-potentials of 1 mM BP-IONPs 
dispersed in different media were determined at 25°C by dynamic and 
electrophoretic light scattering in a Beckman Coulter (Krefeld, Germany) 
DelsaTM Nano C Particle analyzer at scattering angles of 165° and 15°, 
respectively. The fluorescence spectra of diluted BP-IONP solutions (50 µM in 
water) were recorded using a Cary Eclipse fluorimeter (Varian, Darmstadt, 
Germany).  
The hydrodynamic diameter, ?-potential and the fluorescence intensity of the 
dispersed BP-IONPs did not change during storage for at least up to one 
month, nor was release of any low molecular weight iron from the particles 
detectable during storage (data not shown).  
2.3. Cell cultures  
Primary microglial cultures were prepared from astroglia-rich primary cultures 
by tryptic removal of the astrocyte layer using a modification of a published 
method [27]. Astroglia-rich primary cultures were prepared from the whole 
brains of neonatal Wistar rats [28] and three hundred thousand viable cells 
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were seeded per well of a 24-well plate with or without coverslips in 1 mL 
culture medium (90% DMEM, 10% FCS, 20 U/mL of penicillin G and 
20 ?g/mL of streptomycin sulphate) or 1.5 million cells per well of a 6-well 
plate in 2.5 mL medium. The cultures were grown in a cell incubator (Sanyo, 
Osaka, Japan) that contained a humidified atmosphere of 10% CO2/90% air 
and the culture medium was renewed every seventh day. To obtain microglial 
cultures, confluent 14- to 23-day-old astroglia-rich cultures were incubated 
for 30 min with 0.5% (w/v) trypsin in serum-free DMEM. This treatment 
resulted in the detachment of an intact top layer of cells that contain virtually 
all the astrocytes and left a population of firmly attached microglial cells in the 
wells. The microglial cells were washed with 2 mL culture medium and 
cultured in 1.5 mL glia-conditioned medium (GCM; 0.2 µm filtered glia-
conditioned culture medium harvested after 1 d incubation of astroglia-rich 
primary cultures) for additional sixteen to twenty hours before experiments 
were performed. The cultures obtained by this method are highly enriched in 
microglial cells, as more than 98% of the cells in these cultures are positive for 
the microglial marker protein CD11b. 
2.4. Experimental incubations   
If not stated otherwise, microglial cultures on 6-well dishes were incubated at 
37°C with 1 mL of GCM containing BP-IONPs and other compounds in the 
concentrations indicated in the legends of the figures and tables. To test for 
the temperature dependence of BP-IONP uptake, microglial cells were 
incubated at the given temperature with 1 mL GCM containing 20 mM HEPES 
(adjusted to pH 7.4 by addition of 5 M NaOH). After the desired incubation 
period, the media were collected for measurement of extracellular lactate 
dehydrogenase (LDH) activity and the cells were washed once with 1 mL of ice-
cold phosphate-buffered saline (PBS: 10 mM potassium phosphate buffer 
pH 7.4, containing 150 mM NaCl). Cells were either lysed in 1 mL 1% (w/v) 
Triton X-100 in serum-free DMEM for analysis of the LDH activity or in 1 mL 
1% (w/v) sulfosalicylic acid for determination of the glutathione content, fixed 
in 3.5% (w/v) paraformaldehyde in PBS for microscopy or stored dry at -20°C 
until quantification of their iron and protein contents. 
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2.5. Determination of cell viability, protein content and glutathione 
content 
The viability of microglial cultures was determined by quantification of cellular 
and extracellular activity of the cytosolic enzyme lactate dehydrogenase (LDH) 
or by investigating the membrane permeability for propidium iodide (PI). LDH 
activity was determined as previously described [29] with the modification that 
180 µL of lysates or media were used in the assay. For analysis of the 
membrane permeability the cells were incubated with PI as described 
previously [30]. To visualize all cell nuclei present, the cells were 
counterstained with the membrane-permeable Hoechst-dye H33342. An 
increase in the number of PI-positive cells or in the amount of extracellular 
LDH reflects a loss in cell viability. The protein content of the cultures was 
determined according to the Lowry method (Lowry et al. 1951) after 
solubilisation of the cells in 700 µL of 50 mM NaOH using bovine serum 
albumin as a standard. The contents of total glutathione (GSx, amount of GSH 
plus two times amount of glutathione disulfide (GSSG)) and GSSG in cell 
lysates were determined by a modified colorimetric Tietze assay [31]. Control 
experiments revealed that none of these colorimetric assays was affected by 
the presence of IONPs (data not shown). 
2.6. Iron quantification and histochemical Perls´ staining for iron   
The total iron content of cells, media or particle dispersions was determined by 
a colorimetric ferrozine method as previously described [25]. Iron was also 
cytochemically visualized by a modification of the histochemical Perls’ staining 
as previously described [24]. For the co-localization of cellular BP-IONP 
fluorescence with Perls´ staining, the fluorescence pictures were taken before 
the iron staining was completed by diaminobenzidine-nickel enhancement.  
2.7. Activation of microglial NADPH oxidase  
Microglial cells were incubated with 0.5 mL of 1 mM nitroblue tetrazolium 
chloride in GCM with or without 150 µM BP-IONPs for 3 h. To some wells 
50 nM phorbol 12-myristate 13-acetate was added after 2 h of incubation as 
positive control for activation of NADPH oxidase [32]. The formation of blue 
formazan crystals was monitored with an Eclipse TE-2000U fluorescence 
microscope (Nikon, Düsseldorf, Germany). 
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2.8. Immunocytochemical staining   
Cells grown on coverslips in wells of 24-well dishes were washed once with 
1 mL ice-cold PBS and fixed with 3.5% (w/v) paraformaldehyde in PBS for 
10 min at 4°C. If not stated otherwise, the cells were washed thrice (5 min 
each) with PBS between the different steps of the staining procedure. After 
incubating the fixed cells with 0.1% (w/v) glycine in PBS for 5 min at RT, the 
membranes of the cells were permeabilized with 0.3% Triton X-100 in PBS for 
10 min at RT. Incubation of the cells with mouse anti-CD11b (1:100 diluted in 
PBS) was carried out for 2 h at RT in a humidified atmosphere, followed by an 
incubation with the secondary Cy3-coupled goat anti-mouse antibody (1:200 
diluted in PBS) for 30 min at RT. For visualization of the nuclei, the cells were 
treated with DAPI (1 mg/mL in PBS) for 5 min at RT. Prior to mounting the 
coverslips in Mowiol mounting media, an ethanol gradient of 70%, 90% and 
100% in 1 min intervals was applied. Fluorescence images were taken by 
using the Eclipse TE-2000U fluorescence microscope. 
For co-localization of accumulated BP-IONPs with lysotracker the cells were 
pre-incubated for 3 h with 150 µM iron as BP-IONPs, gently washed with 1 mL 
GCM and incubated for 0 or 90 min in GCM before 75 nM lysotracker was 
applied. After 60 min incubation with lysotracker, the cells were washed once 
with 1 mL of PBS and fixed with 3.5% (w/v) paraformaldehyde for 10 min. The 
images of cellular fluorescence for BP-IONPs (excitation: 488 nm, emission: 
500–520 nm) and lysotracker (excitation: 561 nm, emission: 590–620 nm) 
were taken by a Leica SP5 confocal laser scanning microscope (Leica, Wetzlar, 
Germany).  
2.9. Presentation of data  
If not stated otherwise, quantitative data are presented as means ± SD of 
values from at least three experiments that were performed on independently 
prepared cultures. Analysis of significance of the differences between groups of 
data was performed by ANOVA followed by the Dunnetts´ post-hoc test. The 
significance of difference between two sets of data was analysed by the t-test. 
p>0.05 was considered as not significant. 
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3. Results 
3.1. Characterization of BP-IONPs  
BP-IONPs were synthesized as described in the methods section. TEM analysis 
revealed that the synthesized BP-IONPs displayed a spherical morphology with 
a particle diameter of 5 to 20 nm (Fig. 1A). EDX analysis confirmed the 
presence of iron and sulphur, demonstrating successful coating of IONPs with 
the sulphur-containing BP-DMSA (Fig. 1B). Presence of the fluorescent dye BP 
in BP-IONPs was confirmed by fluorescence spectroscopy of the particles that 
showed maxima of 490 nm and 510 nm in the excitation and emission 
spectra, respectively (Fig. 1C). The average hydrodynamic diameter and the ?-
potential of BP-IONPs dispersed in water were 65 ± 4 nm and -49 ± 2 mV, 
respectively (Fig. 1D; Tab. 1).  
For cell experiments, IONPs have to be dispersed in physiological media or 
buffers to maintain the cell viability. Since the composition of the medium can 
strongly affect the properties of engineered NPs [33], we investigated the effects 
of different media on the size and the ?-potential of BP-IONPs. Dispersion of 
BP-IONPs in plain DMEM culture medium caused rapid precipitation of the 
particles as demonstrated by the strong increase in the average hydrodynamic 
diameter of the particles (Tab. 1). This precipitation was not observed for 
DMEM containing 10% FCS or for GCM that also contained 10% FCS. For 
these conditions, the diameter of the particles was doubled (to around 
130 nm) compared to that determined for the water dispersion (65 nm), while 
the ?-potential became more positive to around -9 mV (Tab. 1).  
3.2. Characterization of microglial cell cultures  
The primary microglial cultures prepared by the trypsinization method [27] 
contained cells with the typical amoeboid or bipolar morphologies (Fig. 2A) 
that have previously been described for cultured microglia [8, 9, 27]. 
Immunocytochemical staining with the antibody Ox-42 for the microglial 
marker protein CD11b [8, 23] demonstrated that almost all cells in the 
cultures were positive for this microglial marker (Fig. 2B). 
3.3. Viability of microglial cells after exposure to BP-IONPs  
To test for the consequences of an exposure of cultured microglial cells to BP-
IONPs, the cells were incubated for up to 6 h in GCM with BP-IONPs. While 
the incubation of microglial cells without BP-IONPs for 6 h (Fig. 3A,B) or with 
up to 150 µM BP-IONPs for 3 h (Fig. 3D,E) did at best marginally affect cell 
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viability (Fig. 3A,D) and the cellular protein content (Fig. 3B,E), the incubation 
of microglial cells for more than 3 h with 450 µM or 1500 µM iron as BP-IONPs 
severely compromised the cell viability as shown by the significant loss in 
cellular LDH activity and by the accompanying increase in extracellular LDH 
activity (Fig. 3A,D). The compromised viability of microglial cells that had been 
treated with higher concentrations of BP-IONPs (Fig. 3D) was confirmed by PI 
staining (Fig. 4). After a 3 h exposure to 1500 µM iron as BP-IONPs the 
membranes of the majority of cells were permeable for the dye (Fig. 4K). For 
longer incubations, even BP-IONPs applied in the low concentration of 150 µM 
caused severe permeability of the cells for PI (data not shown). 
Accumulated IONPs have been reported to induce oxidative stress in cultured 
cells [34, 35]. To test whether cultured microglial cells may suffer from 
oxidative stress during exposure to BP-IONPs, we tested for potential 
alterations in the cellular GSH redox state. However, microglial cells that had 
been exposed for 3 h to 150 µM or 450 µM iron as BP-IONPs had almost 
identical cellular GSx values as control cells and did not show any increase in 
cellular GSSG values (Tab. 2) that would indicate a severe oxidative stress.  
3.4. Accumulation of iron from BP-IONPs by cultured microglial cells  
Exposure of microglial cells to BP-IONPs caused a time- and concentration-
dependent increase in the cellular iron content (Fig. 3C,F, Fig. 5), while the 
iron content of microglial cells incubated without BP-IONPs was not altered 
(Fig. 3C,F). After a 3 h incubation with 150 µM and 450 µM iron supplied as 
BP-IONPs, the cellular iron content was increased 4- and 10-fold to 219 ± 52 
and 481 ± 28 nmol iron/mg protein, respectively, compared to the initial iron 
content of 49 ± 65 nmol iron/mg protein (Fig. 3C,F). Visualization of the 
cellular iron content by cytochemical staining for iron by the Perls´ method 
confirmed for BP-IONPs the concentration dependent increase in cell-
associated iron (Fig. 5). While microglial cells that had been incubated without 
BP-IONPs hardly contain Perls´-detectable iron (Fig. 5A), the dark staining of 
precipitates formed in BP-IONP exposed cells became more intense with 
increasing concentration of applied BP-IONPs (Fig. 5C,E,G). For all 
concentrations of BP-IONPs applied, the iron visualized by the Perls´ method 
was almost perfectly co-localized with the BP-fluorescence of the cells (Fig. 5). 
While microglial cells incubated without BP-IONPs did hardly show any 
fluorescence (Fig. 5B), the fluorescence intensity of the cells increased with the 
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concentration of BP-IONPs applied (Fig. 5D,F,H). After incubation of the 
cultures with 450 µM BP-IONPs, all cells in the microglial cultures were Perls´ 
positive for iron (Fig. 5G) and showed a strong BP fluorescence (Fig. 5H).  
To test for the influence of the incubation temperature on the accumulation of 
BP-IONPs by microglial cells, the cells were incubated with BP-IONPs in GCM 
that was pH stabilized at 4°C or 37°C by addition of HEPES. Incubation of 
microglial cells in HEPES-stabilized GCM at 4°C did neither alter the cellular 
protein content (Fig. 6B) nor compromise cell viability (Fig. 6C), but almost 
completely prevented the accumulation of BP-IONPs by microglial cells 
(Fig. 6A). Treatment of microglial cells with the respective 37°C condition led to 
a substantial accumulation of BP-IONPs but the cell viability was also 
compromised as indicated by the increased extracellular LDH activity (Fig. 6C) 
compared to an incubation in HEPES-free GCM. This temperature dependence 
of BP-IONP accumulation in microglial cells was confirmed by Perls´ staining 
and fluorescence microscopy which revealed that hardly any cell in microglial 
cultures that had been exposed to BP-IONPs at 4°C was Perls´ positive or 
showed BP fluorescence (data not shown).  
3.5. Endocytosis and intracellular localization of BP-IONPs  
Microglial cells contain a large number of lysosomal vesicles that can be 
stained with lysotracker (Fig. 7B). In the fluorescence channel used to detect 
BP-fluorescence, these cells showed only a weak autofluorescence (Fig. 7A) 
which was co-localized with the lysotracker-stained lysosomes (Fig. 7B). After 
exposure of the cells to 150 µM BP-IONPs for 3 h, microglial cells revealed a 
strong punctuated fluorescence staining (Fig. 7D), suggesting that most of the 
cellular BP-IONP fluorescence was associated with vesicular structures. 
Lysotracker co-staining revealed that only a part of these BP-IONP positive 
structures were lysosomes (Fig. 7E). However, after a further 90 min 
incubation period of BP-IONP treated microglial cells in NP-free GCM the 
number of large BP-IONP positive vesicle had increased (Fig. 7G) and the 
majority of these vesicles were now positively stained with lysotracker (Fig. 
7H). 
Inhibitors of endocytotic pathways were used to investigate which pathways 
may be involved in the observed accumulation of BP-IONPs by microglial cells. 
EIPA, a known inhibitor of macropinocytosis [36, 37] as well as tyrphostin 23 
and chlorpromazin, inhibitors of clathrin-dependent uptake [36-38], lowered 
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the iron accumulation in BP-IONP treated microglial cells by around 30% 
compared to control conditions (Tab. 3), while combination of these three 
inhibitors reduced the cellular iron contents by almost 60% (Tab. 3). The 
presence of these inhibitors did not lower cell viability as demonstrated by the 
absence of any significant increase in the extracellular LDH activity (Tab. 3). 
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Fig. 1: Characterization of BP-IONPs. A: Transmission electron microscopy 
picture of BP-IONPs. B: Energy dispersive X-ray spectrum of BP-IONPs. C: 
Emission (excitation at 490 nm) and excitation (emission at 510 nm) 
fluorescence spectra of a 50 µM dispersion of BP-IONPs in water. D: Intensity 
distribution of the hydrodynamic diameter of BP-IONPs (1 mM) dispersed in 
water or GCM as determined by dynamic light scattering. 
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Fig. 2: Characterization of primary microglial cultures. A: Light 
microscopical image of a microglia-rich culture. B: Immunocytochemical 
staining of the cultures for the microglial marker protein CD11b. Nuclei were 
counter stained with DAPI. 
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Fig. 3: Consequences of an exposure of microglial cultures to BP-IONPs. 
The cells were incubated without (0 µM) or with 150 µM or 450 µM BP-IONPs 
for up to 6 h (A-C) or for 3 h with the indicated concentrations of BP-IONPs (D-
F) and the cellular and extracellular LDH activities (A,D), the protein content 
(B,E) as well as the specific iron content of the cells (C,F) were determined. 
Indicated is the significance of differences between the values obtained for BP-
IONP-treated cells compared with controls (absence of BP-IONPs) (*p<0.05; 
**p<0.01; ***p<0.001). 
Results 
108 
 
Fig. 4: Effects of BP-IONPs on the membrane integrity of microglial cells. 
The cells were incubated without (A-C) or with 150 µM (D-F), 450 µM (G-I) or 
1500 µM (J-L) iron as BP-IONPs for 3 h. Shown are the phase contrast images 
of the cells (A,D,G,J), the PI staining which indicates nuclei of cells with 
permeabilized membranes (B,E,H,K) and the Hoechst 33342 (H33342) 
staining which identifies the nuclei of all cells present (C,F,I,L). The scale bar 
in L represents 100 µm and applies to all panels. 
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?
Fig. 5: Perls´ iron staining and BP-fluorescence of cultured microglial 
cells after exposure to BP-IONPs. The cells were incubated without (control, 
A,B) or with 45 µM (C,D), 150 µM (E,F) or 450 µM (G,H) of iron as BP-IONPs. 
Shown are overlays of the phase contrast image of the cells with the 
transmission light images of the Perls´ staining for cellular iron (A,C,E,G) and 
the BP fluorescence images (B,D,F,H) The size bar in panel H represents 
50 µm and applies to all panels. 
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Fig. 6: Temperature dependent uptake of iron from BP-IONPs by cultured 
microglial cells. The cells were incubated for 3 h without (control) or with 
150 µM of iron as BP-IONPs in GCM at 37°C or in GCM-HEPES at 37°C or 
4°C. The specific iron content (A), the protein content (B) and the extracellular 
LDH activity (C) were measured. Indicated is the significance of differences 
compared to the values obtained for cells that had been incubated at 37°C in 
GCM-HEPES (**p<0.01). 
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Fig. 7: Confocal co-localization of BP-IONPs and lysosomes in microglial 
cells. Microglial cells were incubation with lysotracker (LT) for 1 h either 
without prior incubation with BP-IONPs (control, A-C) or directly (D-E) or 90 
min (G-I) after a 3 h loading of the cells with 150 µM BP-IONPs. The scale bar 
in I represents 10 µm and applies to all panels.  
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Table 1: Hydrodynamic diameter and ?-potential of BP-IONPs in 
different media. 
Medium 
Hydrodynamic 
diameter (nm) n 
?-potential 
(mV) n 
         
H2O 65 ±     4 5 -49 ± 2 4 
DMEM 2221 ± 332 4 -18 ± 0 4 
DMEM + FCS 128 ±   54 4 -9 ± 1 4 
GCM 139 ±     9 3 -8 ± 3 3 
         
The hydrodynamic diameter and the ?-potential were determined for 
dispersions of BP-IONPs in the given media that contained 1 mM iron 
as BP-IONPs. The data represent mean values ± SD of n independently 
performed experiments. 
 
 
Table 2: Effects of BP-IONPs on the glutathione content of 
cultured microglial cells. 
BP-IONP GSx content GSSG content Protein content 
(µM) (nmol/mg)  (nmol GSx/mg) (µg/well)  
          
initial 15.3 ± 3.2 0.2 ± 0.2 68 ± 14 
0 10.3 ± 1.9 0.0 ± 0.0 84 ± 12 
150 10.7 ± 1.7 0.2 ± 0.2 80 ±   7 
450 10.2 ± 2.5 0.2 ± 0.2 85 ±   4 
          
Cultured microglial cells were incubated for 3 h without (0 µM) or 
with 150 µM or 450 µM of iron as BP-IONPs and the specific 
contents of total glutathione (GSx) and GSSG as well as the 
protein content were measured. The data represent mean values ± 
SD of 3 experiments performed on independently prepared 
cultures. 
  
Table 3: Effects of endocytosis inhibitors on the cell viability and the accumulation of BP-IONPs by cultured 
microglial cells. 
The cells were incubated for 3 h with 150 µM iron applied as BP-IONPs in the absence or the presence of the indicated 
endocytosis inhibitors. Since all inhibitors were applied from concentrated stock solutions in dimethyl sulfoxide (DMSO), 
the effect of the respective DMSO control was also investigated. The data represent mean values ± SD of n experiments 
performed on independently prepared cultures. Indicated are the significances between values obtained for cells treated 
with the indicated inhibitor(s) and the respective control (*p<0.05; **p<0.01; ***p<0.001). 
R
e
s
u
lts
Inhibitor/ 
Treatment 
Concentration 
 
Cellular LDH 
activity 
Extracellular 
LDH activity 
Protein 
content 
Specific iron content n 
   (µM) (% of total)  (% of total) (µg/well)  (nmol/mg) (% of control)  
Control (1xDMSO)   90 ± 11 10.4 ± 10.7 55 ± 12 257 ±  33 100 ±   0 3 
EIPA   25  98 ±   1 1.5 ±   1.2 66 ± 22 186 ± 16 ** 73 ± 10 * 3 
Tyrphostin 23 100  100 ±   1 0.1 ±   0.1 63 ± 18 191 ± 25 ** 74 ±   4 * 3 
Chlorpromazine  10  99 ±   2 1.3 ±   1.5 70 ± 13 189 ±   9 ** 74 ±   7 * 3 
Control (3xDMSO)   98 ±   2 2.5 ±   2.3 76 ± 23 220 ± 83 100 ±   0 5 
EIPA +   25 +                  
Tyrphostin 23 + 100 +                  
Chlorpromazin        10      98 ±   3 2.0 ±   2.1 67 ± 20 * 87 ± 26 *** 42 ± 15 *** 5 
   
 
 
  
 
  
 
  
 
  
 
 
 
1
1
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4. Discussion 
4.1. Characterization of BP-IONPs  
Fluorescent BP-IONPs were successfully synthesized and coated with BP-
labelled DMSA as previously shown for unlabelled DMSA [25, 39, 40]. DMSA 
has been reported to form a cage like structure around the IONPs by binding 
of the carboxyl groups of DMSA to the nanoparticle surface and by formation 
of disulfide bridges between adsorbed DMSA molecules [26, 41]. Complete 
derivatization of the BP applied labelled only 7.5% of the thiol groups of the 
available DMSA, thereby leaving sufficient DMSA thiol groups for the 
formation of a disulfide-linked cage around the core of the IONPs. The 
characterization of BP-IONPs by TEM and dynamic light scattering revealed 
the presence of individual particles of around 10 nm diameter which had 
formed small aggregates in dispersion, as previously also reported for DMSA-
coated IONPs [25]. Fluorescence spectroscopy confirmed the presence of the 
fluorescent dye BP in the particles, as BP-IONPs showed the fluorescence 
maxima around 490 nm and 510 nm in the excitation and emission spectra, 
respectively, that were also recorded for BP by us (data not shown) and others 
[42, 43].  
BP-IONPs were not stably dispersed in plain DMEM culture medium. Reason 
for this observation may be the high ionic strength of this medium and/or the 
presence of phosphate which caused precipitation of DMSA-coated IONPs 
(data not shown). However, presence of serum prevented the precipitation of 
BP-IONPs, most likely by forming a protein corona around the particles as 
previously described for AgNPs [44, 45] and IONPs [46, 47]. This hypothesis is 
supported by the increase in hydrodynamic diameter as well as by the 
positivation of the ?-potential of BP-IONPs dispersed in serum-containing 
media.  
4.2. Microglial cell cultures  
Highly purified microglial cultures were generated by tryptic removal of the 
astrocyte layer from astroglia-rich primary cultures. Cell morphology and 
immunocytochemical staining confirmed literature data [8, 27] demonstrating 
that the cultures obtained were highly enriched for microglial cells. Although 
microglial cells in culture are described to be in an activated mode due to the 
artificial environment [7], the microglial cultures used in our study could be 
further activated by incubation with a phorbol ester (data not shown) which 
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induces superoxide generation by NADPH oxidase [32, 48]. However, no 
enhanced superoxide production was observed for microglial cultures after 
exposure to BP-IONPs (data not shown) which confirms literature data that 
cultured microglial cells are not activated by an exposure to IONPs [23]. 
4.3. Accumulation of BP-IONPs by viable microglial cells   
Exposure of microglial cells to moderate concentrations of BP-IONPs (up to 
450 µM) for up to 3 h did not compromise cell viability, whereas higher 
concentrations of IONPs or elongated incubation periods led to a severe loss in 
cell viability. This is consistent with literature data described for IONP-treated 
secondary microglial cultures [13, 23]. Quantification of cellular iron contents 
of BP-IONP treated microglial cells revealed a concentration dependence of BP-
IONP accumulation, which was confirmed by fluorescence microscopy and 
cytochemical Perls´ staining for iron. The strict co-localization of fluorescence 
and iron deposits suggests that under the conditions used most of the 
accumulated particles remained intact after uptake.  
Cultured viable microglial cells increased their cellular iron content after a 3 h 
incubation with 450 µM BP-IONPs by 10-fold. This cellular amount of 
accumulated IONPs of around 500 nmol/mg protein, which represented less 
than 10% of the iron applied as BP-IONPs, appears to be the maximal 
amounts of accumulated IONPs that can be tolerated by viable microglial cells, 
since higher concentrations of IONPs or longer incubations that led to higher 
specific cellular iron contents compromised the cell viability. This observation 
is consistent with the view that microglial cells take up particles until they die 
[13]. The loss in cell viability upon exposure to high concentrations of IONPs 
may be a consequence of a rapid liberation of iron ions from the accumulated 
particles, as low molecular weight iron has been described to be toxic for 
microglial cells [49, 50] and to cause detachment of cells [51]. This hypothesis 
is consistent with the observation that cellular BP-IONP fluorescence in 
microglial cells was co-localized with lysosomes where the low pH has been 
described to facilitate IONP-degradation by liberation of iron ions [52]. 
To test to which extend the determined cellular iron of IONP-treated microglial 
cells represented internalised iron or IONPs that were bound extracellularly to 
the cell membrane, the cells were exposed to BP-IONPs at 4°C, since this low 
temperature is known to slow down transport processes across the membrane 
and the internalisation of IONPs [25, 53, 54]. After incubation at 4°C, only 
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20% of the cellular iron contents of the respective 37°C incubation were 
observed, suggesting that only around 20% of the cellular iron determined for 
BP-IONP treated microglial cells can be considered as externally attached. This 
is consistent with data obtained for the uptake of other types of fluorescent 
IONPs by microglial cells [23]. In contrast, membrane-attached IONPs 
represented around 50% of the total cellular iron determined for IONP-treated 
astrocytes [25]. Thus, cultured microglial cells appear to be more efficient to 
internalise membrane-bound IONPs or are less efficient to bind IONPs than 
cultured astrocytes, although the specific capacity of cultured astrocytes to 
accumulate IONPs is much higher [25, 53] than that of cultured microglial 
cells. 
4.4. Mechanisms of BP-IONP uptake into microglial cells  
The uptake of BP-IONPs into vesicles and the subsequent co-localization of 
BP-IONPs in microglial cells with lysosomes suggest that endocytotic 
processes are involved in the accumulation of BP-IONPs into microglial cells. 
Although microglial cells have the capacity for phagocytosis [8], this process 
appears not to contribute substantially to the observed BP-IONP accumulation 
by cultured microglial cells. At least the phagocytosis inhibitor cytochalasin D 
which is described to inhibit ?-synuclein-aggregate uptake in microglia [55] 
did not affect the BP-IONP accumulation by microglial cells (data not shown). 
Since the aggregates of BP-IONPs formed in GCM had an average size of 
140 nm, they may be too small to be taken up by phagocytosis, since this 
process has been discussed to be predominantly involved in uptake of 
particles larger than 200 nm [56], while smaller particles are taken up by 
endocytotic pathways [57]. Indeed, tyrphostin 23, chlorpromazin and EIPA, 
inhibitors of macropinocytosis and clathrin-dependent endocytosis [38, 58, 59] 
significantly lowered the accumulation of BP-IONPs into microglial cells by 
around 60% in an additive fashion, suggesting that these two endocytotic 
pathways contribute to the uptake of BP-IONPs by microglial cells. This is in 
line with a recent report that demonstrates also a clathrin-dependent uptake 
of quantum dots into microglial cells [18]. However, it should be stressed here 
that the specificity of inhibitors that are commonly used to identify endocytotic 
pathways is still under debate [36, 37].  
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4.5. Conclusions  
In summary, fluorescent BP-IONPs were synthesized and characterized as 
tools to investigate IONP uptake into cultured microglial cells. These cells 
efficiently accumulated BP-IONPs as demonstrated by quantification of 
cellular iron contents as well as the co-localization of cellular iron and cellular 
fluorescence. The localization of BP-IONPs in lysosomes as well as the 
inhibition of BP-IONP uptake by endocytosis inhibitors demonstrates that the 
BP-IONPs are taken up into microglial cells by endocytosis and enter the 
lysosomal pathway. Although the low pH of the lysosomes may liberate some 
iron from the accumulated BP-IONPs, the cells remained viable after exposure 
to moderate concentrations of the particles and did not show any indications 
for enhanced activation or oxidative stress. Thus, microglial cells may act as a 
first defence line in brain that fast and efficiently takes up IONPs, thereby 
helping to protect the brain against damage by IONPs and IONP-derived iron. 
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3 SUMMARIZING DISCUSSION 
This thesis investigated the effects of metal-containing NPs on cultured brain 
astrocytes and microglia, as those cells can be considered as first lines of 
defense against potential NP-derived effects in brain that protect other brain 
cells from damage. Due to the high prevalence rate of AgNPs in consumer 
products and the medical importance of IONPs those two types of NPs are of 
high relevance. Therefore this thesis focused on the investigation of the 
consequences of an exposure of brain cells to AgNPs and IONPs. 
3.1 UPTAKE AND METABOLISM OF SILVER NANOPARTICLES BY ASTROCYTES 
After peripheral application, a distribution of AgNPs throughout the whole 
body, including the brain, has frequently been reported (table 1.1). In addition, 
increased silver levels in brain cells upon treatment with AgNPs cause 
neurotoxicity and cognitive impairment in fish and rats (Kashiwada 2006, 
Asharani et al. 2008, Hadrup et al. 2012, Lee et al. 2012, Liu et al. 2012a). 
However, only little is known on the mechanisms behind these observed 
effects. The consequences of an exposure to AgNPs have been studied in CA1 
neurons in brain slices, where the excitability and the signal transduction 
were altered by the depression of K+- and Na+-channels (Liu et al. 2009, Liu et 
al. 2011, Liu et al. 2012b), while in primary neural cells, mainly consisting of 
neurons and astrocytes, toxicity, oxidative stress and calcium signals have 
been observed (Haase et al. 2012). This thesis provides new insights into the 
biocompatibility and metabolism of PVP-coated AgNPs in astrocyte-rich 
primary cultures.  
Astrocytes efficiently accumulated silver from AgNPs in a time- and 
concentration-dependent manner (chapter 2.1) as also described for the 
uptake of other NPs like IONPs (chapter 1.5, Geppert et al. 2009, Geppert 
et al. 2011, Lamkowsky et al. 2012) or polymer NPs (Chang et al. 2012). 
The capacity of astrocytes to accumulate silver from AgNPs was 
substantially higher compared to that of other cells types. For example, it 
exceeded that of cultured A549 lung cancer cells (Foldbjerg et al. 2011) by 
almost 20-fold. 
The uptake of NPs by astrocytes is an energy-dependent process that 
involves endocytotic processes (chapter 1.5, Hohnholt et al. 2010b, Pickard 
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et al. 2011, Lamkowsky et al. 2012, Geppert et al. 2013). Vesicular 
structures filled with NPs including AgNPs have frequently been shown by 
TEM in astrocytes (Geppert et al. 2011, Pickard et al. 2011, Haase et al. 
2012, Jenkins et al. 2013). However, the mechanisms involved in the 
uptake of NPs have been demonstrated only for IONPs so far (Pickard et al. 
2011, Lamkowsky et al. 2012, Geppert et al. 2013). The uptake of AgNPs 
into astrocytes has been investigated in detail for the first time in this 
thesis (chapter 2.1). Lowering of the incubation temperature from 37°C to 
4°C and thereby inhibiting active and energy-dependent uptake 
mechanisms decreased the cellular silver content by 80%. The active 
uptake of AgNPs into astrocytes was in part mediated by macropinocytosis 
(MP) and via the endosomal pathway as inhibition of those pathways 
significantly lowered the AgNP-uptake.  
Comparing the endocytotic uptake of IONPs and AgNPs into astrocytes 
reveals, that the effects of the individual endocytosis inhibitors seem to be 
dependent on the incubation conditions, e.g. presence of serum, and the 
particles used (table 3.1). Therefore, general statements can hardly be 
made which pinpoint an individual pathway for NP uptake by astrocytes. 
However, at least the caveolin-mediated endocytosis (CvME) seems not to 
participate in the uptake of NPs into astrocytes as inhibitors of this 
pathway (Filipin III and Methyl-?-cyclodextrin) were not effective in 
preventing NP uptake in any of the described studies (table 3.1). In 
addition, the inhibitory potential of endocytosis inhibitors appears to be 
rather cell-type specific, as compounds like wortmannin and chlorpromazine, 
that were ineffective in inhibiting the AgNP uptake in astrocytes (chapter 2.1) 
partially prevented AgNP uptake into IMR-90 human lung fibroblasts 
(AshaRani et al. 2009), human mesenchymal stem cells (Greulich et al. 
2011b), U251 human glioblastoma cells (AshaRani et al. 2009) and the mouse 
macrophage cell line J774A.1 (Wang et al. 2012). The NP-size also seems to 
play an important role for the inhibitory potential of endocytosis inhibitors, as 
upon application of very small AgNPs with a diameter of 5 nm to U937 
macrophages, endocytotic uptake could neither be prevented by inhibition of 
CME nor by blocking of MP or CvME. The majority of these particles was 
discussed to be taken up via passive membrane penetration (Kim and Choi 
2012). However, it should be considered, that the specificity of the described 
inhibitors for an individual endocytotic pathway is questionable (Ivanov 2008). 
  
Table 3.1: Studies reporting the contribution of endocytotic pathways in NP uptake into astrocytes. 
EIPA: 5-(N-ethyl-N-isopropyl)amiloride 
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NP type Size 
(nm) 
Inhibitors affecting  
NP uptake 
Inhibitors not affecting  
NP uptake 
Reference 
Serum present during the incubation 
PVP-AgNP 75 Chloroquine (1 mM) 
Amiloride (1 mM) 
Methyl-?-cyclodextrin (2.5 mM) 
3-Methyladenine (2.5 mM) 
Wortmannin (100 nM) 
EIPA (25 µM) 
Chlorpromazine (20 µM) 
chapter 2.1 
Carboxyl-
modified 
Polystyrene-
IONP 
360 Tyrphostin 23 (350 µM) 
Dynasore (80 µM) 
Amiloride (1 mM) 
EIPA (100 µM) 
Filipin III (5 µg/ml) Pickard and Chari (2010a) 
DMSA-IONP 70 Chlorpromazine (20 µM) 
Wortmannin (100 nM) 
EIPA (25 µM) 
3-Methyladenine (2.5 mM) 
Geppert et al. (2013) 
Serum absent during the incubation 
DMSA-IONP 70 -- Chlorpromazine (20 µM) 
EIPA (25 µM) 
Wortmannin (100 nM) 
3-Methyladenine (2.5 mM) 
Geppert et al.(2013) 
DMSA-IONP 60 -- Chlorpromazine (20 µM) 
EIPA (25 µM) 
Lamkowsky et al. (2012) 
1
2
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In the studies described within this thesis, astrocytes were shown to 
accumulate PVP-coated AgNPs very efficiently without any acute or delayed 
loss in cell viability. This is in contrast to data on peptide-coated AgNPs that 
induced toxicity in astrocytes (Haase et al. 2012). In addition, PVP-coated 
AgNPs induced toxicity in other cell types, like in human mesenchymal stem 
cells (hMSCs) (Greulich et al. 2009). Therefore, also the toxic potential of 
AgNPs appears to strongly depend on the NP-composition and the individual 
cell-types investigated.  
The reported cell toxicity of AgNPs is likely to originate from silver ions (Ag+) 
that were released from AgNPs (Johnston et al. 2010, Kittler et al. 2010). Ag+ 
have been shown to be much more toxic than AgNPs for many cells types, like 
A549 lung cancer cells, THP-1 monocytes, hMSCs, HepG2 cells, Chang liver 
cells (CLC), PC12 cells or trout gill cells (Foldbjerg et al. 2009, Greulich et al. 
2009, Kim et al. 2009, Kittler et al. 2009, Foldbjerg et al. 2011, Powers et al. 
2010b, Farkas et al. 2011, Piao et al. 2011) and also for astrocytes (chapter 
2.1). As evident from figure 3.1, the resistance towards Ag+ was similar in 
astrocytes and other cell types, but astrocytes appeared to have a much higher 
capacity to survive a treatment with AgNPs and tolerated AgNP concentrations 
that outranged toxic Ag+ concentrations by at least 10-fold, whereas in other 
cell types already 1- to 6-times higher concentrations of AgNPs compared to 
Ag+ led to a significant loss in viability (figure 3.1).  
Differences in the release of Ag+ may also explain the observed discrepancies 
in toxicity of PVP- and peptide-coated AgNPs in astrocytes (chapter 2.1, Haase 
et al. 2012) as it could be possible that the peptide coat is degraded faster or is 
less dense than the PVP-coat supporting a faster liberation of Ag+ and 
subsequently a higher toxicity of peptide-coated AgNPs.  
Oxidative stress has frequently been described as a consequence of an 
incubation of various cell lines from human, rat or mouse origin with AgNPs 
(table 3.2). Interestingly, oxidative stress is described for AgNPs with various 
coatings regardless of the size of the particles (table 3.2). Therefore the 
potential to induce oxidative stress in cell lines appears to be a general 
property of AgNPs which is likely to originate from the Ag+ released from the 
particles as silver in low molecular form is known to induce oxidative stress 
(Powers et al. 2010b).  
?
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Besides this thesis only few studies describe the effects of AgNPs on primary 
cells (Arora et al. 2009, Greulich et al. 2011a, Haase et al. 2012). The cellular 
antioxidative machinery has been reported to be altered in all of those studies 
upon application of AgNP concentrations between 10 and 30 µg/ml. In 
primary mouse fibroblasts and primary liver cells oxidative stress due to a 
24 h-incubation with 30 µg/ml AgNPs has been described to elevate cellular 
GSH levels (Arora et al. 2009), whereas in peripheral blood mononuclear cells 
(PBMCs) and mixed neural cultures ROS has been detected already upon an 
exposure to 10 µg/ml AgNPs for 24 and 3 h, respectively (Greulich et al. 
2011a, Haase et al. 2012). This is in contrast to the data obtained in this 
thesis, where neither shift in the cellular GSH to GSSG ratio nor a cellular 
depletion of GSH or ROS formation were detectable in astrocytes upon 
treatment with 10.8 µg/ml (100 µM) AgNPs for 4 h or after a subsequent 
recovery phase of up to 1 week. This again reveals that the effects observed 
upon treatment of cells with AgNPs dependent strongly on the NP-composition 
and cell-type used. 
A B
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Figure 3.1: Difference in the toxicity observed in various cell types after 
application of AgNPs and Ag+. Panel A shows the lowest concentrations of AgNPs 
and Ag+ applied, that resulted in a significant loss in viability. Panel B shows the 
ratio of the lowest reported toxic concentration of AgNPs to Ag+. Data are compiled 
from chapter 2.1 of this thesis (astrocytes), Greulich et al. 2009 (hMSC a), Kittler et 
al. 2009 (hMSC b), Foldbjerg et al. 2009 (THP-1), Foldbjerg et al. 2011 (A549), 
Farkas et al. 2011 (trout gill cells), Kim et al. 2009 (HepG2), Miura and Shinohara 
2009 (HeLa), Piao et al. 2011 (CLC) and Powers et al. 2010b (PC12) and represent 
results obtained by different toxicity assays. However, it should be noted that the 
values for the onset of toxicity in each cell type depends on the assay used, as 
shown for HepG2 cells, where filled bars represent values from the alamar blue 
test, whereas the dashed bars show data from the MTT assay. In the studies on 
astrocytes and PC12 cells the arrows indicate underestimation of the values as no 
toxicity was observed in the highest concentrations of AgNPs tested. 
  
Table 3.2: Exposure of different cell lines to AgNPs induces oxidative stress. 
#: shortest incubation time after which oxidative Stress was detected; §: lowest concentration at which a sigificant change in 
oxidative stress or antioxidative parameters was observed; n/a: not availabe; GSH: glutathione; ROS: reactive oxygen species; 
?: increased; ?: decreased. 
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Cell type NP size (nm) NP coat Time# Concentration§ Toxicity Effects References 
A431 7-20 n/a 24 h  6.25 µg/ml yes GSH ?; 
lipid peroxidation ? 
Arora et al. (2008) 
BEAS-2B 43-260 Pt/Pd 24 h  0.01 µg/ml no ROS ? Kim et al. (2011) 
BRL3A 15 n/a 24 h  25 µg/ml yes GSH ?; ROS ? Hussain et al. (2005) 
 100 n/a 24 h  25 µg/ml yes GSH ?; ROS ?  
HaCaTT 68.5 n/a 0.5 h  7.81 µg/ml no ROS ? Mukherjee et al. (2012) 
    n/a 24 h  200 µg/ml yes GSH ?   
hCLS 28-35 n/a 0.5 h  n/a n/a GSH ?, ROS ? Piao et al. (2011) 
HCT 116  n/a n/a 12 h  n/a n/a ROS ? Hsin et al. (2008) 
HeLa 5-10 n/a 4 h  2.5 µg/ml no ho-1 gene ? Miura and Shinohara (2009) 
HeLa 65.5 n/a 1 h  0.625 µg/ml no ROS ? Mukherjee et al. (2012) 
     24 h  25 µg/ml n/a GSH ?   
HepG2 10 none confluency 
of control 
0.12 µg/ml n/a GSH ? Nowrouzi et al. (2010) 
     0.24 µg/ml n/a NO ?   
HepG2 5-10 n/a 1 h  0.2 µg/ml n/a ROS ? Kim et al. (2009) 
HepG2 5 PVP 2 h  1 µg/ml yes ROS ? Liu et al. (2010) 
 20 PVP 2 h  10 µg/ml yes ROS ?  
  50 PVP 2 h  10 µg/ml yes ROS ?   
1
3
0
 
  
Table 3.2 continued: Exposure of different cell lines to AgNPs induces oxidative stress. 
#: shortest incubation time after which oxidative stress was detected; §: lowest concentration at which a sigificant change in 
oxidative stress or antioxidative parameters was observed; n/a: not availabe; GSH: glutathione; ROS: reactive oxigen species; 
?: increased; ?: decreased. 
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Cell type NP size (nm) NP coat Time# Concentration § Toxicity Effects References 
HepG2 69 ± 5 none 5 h  10% v/v n/a ROS ? Stevanovic et al. (2011) 
  45 ± 5 PGA 5 h  10% v/v n/a ROS ?   
HT-1080 7-20 n/a 24 h  6.25 µg/ml yes GSH ?; 
lipid peroxidation ? 
Arora et al. (2008) 
NIH3T3  n/a n/a 6 h  n/a n/a ROS ? Hsin et al. (2008) 
PC12 10 citrate 4 d  3.24 µg/ml yes ROS ? Powers et al. (2010a) 
 10 PVP 4 d  3.24 µg/ml n/a ROS ?  
  50 PVP 4 d  1.08 µg/ml n/a ROS ?   
RAW 264.7 69 ± 30 FBS 24 h  0.4 ppm no GSH ?; NO ? Park et al. (2010) 
THP-1 69 (TEM), 
100-200 
(DLS) 
none 6 h  5 µg/ml yes ROS ? Foldbjerg et al. (2009) 
1
3
1
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Upon exposure to an excess of metals, including application of metal 
containing NPs, astrocytes have frequently been shown to upregulate proteins 
that allow metal storage like Ft or metallothioneins (MTs) (chapter 1.5, chapter 
2.2, Tiffany-Castiglioni et al. 2001, Tiffany-Castiglioni and Qian 2001, Dringen 
et al. 2007, Jones 2012, Scheiber and Dringen 2013) and/or proteins like 
heme oxigenase-1 (HO-1) that provide protection from the adverse effects that 
may arise from those metals (Ni et al. 2011). 
The strong resistance of astrocytes against AgNP-derived toxicity is likely to be 
due to their high metal storing capacity which is increased by upregulation of 
metal storage proteins like MTs. The molecular mechanisms which induce this 
upregulation are not known so far. An involvement of the metal regulatory 
transcription factor 1 (MTF-1) seems likely which could be activated by zinc 
ions that were replaced by silver ions in MTs, since silver has a much higher 
affinity to MTs than zinc (Floria?czyk 2007). Activated MTF-1 would bind to 
metal response elements in the MT gene and trigger its synthesis (Vašák and 
Meloni 2011). Another possible way of MT upregulation involves the binding of 
the transcription factor Nrf-1 to antioxidative response elements within the 
MT-gene which can be triggered by oxidative stress (Ohtsuji et al. 2008, 
Reisman et al. 2009). A similar pathway could also result in an upregulation of 
HO-1 as described for neural cells (Haase et al. 2012), although HO-1 is not 
regulated via Nrf-1, but by Nrf-2, a member of the same family of transcription 
factors, which also binds to antioxidative response elements in the genes of 
target proteins (Syapin 2008).  
In mixed neural cell cultures which contain mainly neurons and astrocytes an 
induction of the cytoprotective HO-1 was first seen after 8 h and increased 
further after 12 and 24 h (Haase et al. 2012). A significant induction of MTs in 
astrocyte cultures was visible after 24 h and increased strongly after 72 h and 
168 h (chapter 2.2). The fast regulation of HO-1 and slightly delayed increase 
in MTs may provide optimal protection of the cells against Ag+-derived toxicity 
or ROS.  
Figure 3.2 summarizes the current knowledge on the handling of AgNPs by 
astrocytes. 
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Figure 3.2: Handling of silver nanoparticles by cultures astrocytes. Astrocytes 
efficiently accumulate silver applied as AgNPs by endocytotic mechanisms but other 
uptake mechanisms appear to be involved in the AgNP uptake as well. The 
intracellular presence of AgNPs coincides with the upregulation of MTs and HO-1 and 
induces the release of a calcium reponse in the cells. This is likely to be due to the 
liberation of Ag+ from the particles. The cellular presence of AgNPs may also lead to 
the formation of ROS.  
 
3.2 CONSEQUENCES OF AN ACCUMULATION OF IRON OXIDE NANOPARTICLES 
BY MICOGLIAL CELLS 
The uptake of IONPs by microglia has frequently been shown in vivo and in 
cell lines (table 1.1), while only limited data are available on the effects of 
IONPs on primary or secondary microglial cells (chapter 2.3, Fleige et al. 
2001, Pickard and Chari 2010b). This thesis for the first time gives 
quantative data on the uptake of IONPs by primary microglial cells of rat 
brain and provides new information on the localization of fluorescent 
IONPs in the cells. 
Microglia efficiently took up BP-DMSA-coated IONPs in a time-, 
concentration- and temperature-dependent manner, confirming literature 
data (Fleige et al. 2001, Pickard and Chari 2010b). Within an incubation 
for 3 h with 450 µM iron as BP-DMSA-coated IONPs viable microglia 
increased their celluar iron content by 10-fold to around 500 nm/mg 
protein. This seems to be the maximal amount of intracellular iron which 
could be tolerated by the cells as a further increase led to a loss in 
viability. This supports literature data, where microglia only survived short 
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incubations of 30 or 120 min with high concentrations of 18 mM or 3 mM 
iron as Texas red-labelled IONPs, respectively, but higher concentrations 
or longer exposure times led to cell death (Fleige et al. 2001). Incubations 
with 20 µg/ml carboxyl-modified Nile red-fluorescent polystyrene-IONPs, 
which contain only 15-20% iron, however, were tolerable for microglial 
cells for even 24 h (Pickard and Chari 2010b). Due to the different time 
frames investigated, a direct comparison of the toxic effects of the different 
IONP-types is not possible, but it seems that the ability of microglial cells 
to tolerate internalized IONPs over time depends on the iron content the 
cells are exposed to. 
The observed toxic effects of IONPs are likely to originate from metal ions 
released from the particles, as described for other NPs (Johnston et al. 
2010, Kittler et al. 2010). The release of ions from NPs due to degradation 
of the particles in microglia can be expected to appear rather fast, as 
already after 90 min the majority of accumulated BP-DMSA-coated IONPs 
were co-localized with lysosomes (chapter 2.3), where the degradation of 
IONPs is facilitated by the low pH (Levy et al. 2010). A degradation of 
polystyrene-IONPs in microglial lysosomes has also been shown by TEM 
imaging (Jenkins et al. 2013). Therefore the amount of low molecular iron 
in the cells is likely to increase quickly to levels that are known to induce 
cytotoxicity in microglial cells (Zhang et al. 2006, Oshiro et al. 2008, 
Rathore et al. 2012). Thus, microglia appear to accumulate IONPs very 
efficiently, but due to their ability to quickly degrade those particles, the 
cells are liklely to generate high cellular levels of low molecular iron which 
they cannot tolerate over time.  
Other cell types in brain who are not as specialized on degradation of 
debris should not, to the same extent, be affected by IONPs and IONP-
derived low molecular iron. Astrocytes, which are described to be the metal 
storing cells in the brain (Tiffany-Castiglioni and Qian 2001, Dringen et al. 
2007, Tiffany-Castiglioni et al. 2011, Scheiber and Dringen 2013), should 
tolerate iron and IONPs (Geppert et al. 2011, Pickard et al. 2011, 
Lamkowsky et al. 2012, Geppert et al. 2013) much better than microglia 
(chapter 2.3). Indeed, comparable studies on astrocytes (Geppert et al. 
2011, Pickard et al. 2011, Lamkowsky et al. 2012, Geppert et al. 2013) and 
microglia (chapter 2.3, Pickard and Chari 2010b) utilizing either carboxyl-
modified Nile red-fluorescent polystyrene-IONPs (Pickard and Chari 2010b, 
Summarizing discussion 
135 
Pickard et al. 2011) or DMSA-coated IONPs (chapter 2.3, Geppert et al. 
2011, Lamkowsky et al. 2012, Geppert et al. 2013) revealed that a 
concentrations of IONPs that resulted in a loss in viability in microglia did 
not induce toxicity in astrocytes. For DMSA-coated IONPs even an 
application of 10-times higher iron concentrations than that toxic for 
microglia (450 µM, chapter 2.3), did not result in cell death of astrocytes 
(Geppert et al. 2011, Lamkowsky et al. 2012, Geppert et al. 2013).  
The observed enhanced toxicity of microglia compared to astrocytes might 
be due to the observation, that microglia accumulate IONPs much faster 
than astrocytes and therewith earlier reach a maximal IONP-load which 
can be tolerated without a loss in viability. Astrocytes were reported to 
accumulate DMSA-coated IONPs with a rate of 24 ± 4 nmol/(h*mg) upon 
incubation with 1 mM IONPs (Geppert et al. 2013), whereas microglia 
accumulated similar particles at an almost doubled rate of 45 ± 4 
nmol/(h*mg) from only 450 µM IONPs applied (chapter 2.3). This 
observation is consistent with studies on low molecular iron. Within 6 h 
microglia accumulated about 10-times more low molecular iron compared 
to astrocytes (Bishop et al. 2010) and concentrations of iron that were toxic 
for microglia did to not impair the viability of astrocytes (Rathore et al. 
2012). Similar effects have also been shown for peripheral cells. Phagocytes 
were shown to be much more sensitive to NPs than non-phagocytotic cells 
due to their better ability to efficiently accumulate and internalize NPs 
(Herd et al. 2011, Mohamed et al. 2011, Rabolli et al. 2011, Fedeli et al. 
2013). 
The mechanisms behind the observed toxicity of IONPs in mircoglia, 
however, remain to be elucidated. Even though upon uptake of IONPs in 
microglia enhanced levels of ROS have been detected in the cell line BV-2 
(Wang et al. 2011b), oxidative stress seems not to be the cause for the 
toxicity of IONPs observed in primary microglia. At least neither a shift in 
the cellular GSH to GSSG ratio nor a depletion of cellular GSH were 
detected in those cells upon treatment with sub-toxic concentrations of 
IONPs. 
The uptake of IONPs into microglia is described to be dependent on 
clathrin-mediated endocytosis (CME) and macropinocytosis (MP) (chapter 
2.3) as well as phagocytotic uptake (Wang et al. 2011b). However, the 
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involvement of phagocytotic pathways was concluded from TEM pictures 
where NP-filled vesicles were shown that could also originate from 
endocytotic uptake. At least in our studies inhibition of phagocytosis did 
not result in a reduced IONP uptake in microglia (data not shown). For 
astrocytes clathrin-mediated endocytosis (CME) and macropinocytosis (MP) 
have also been identified to be responsible for the uptake of similar 
particles compared to those discussed in chapter 2.3 from serum 
containing media (Geppert et al. 2013). However, a part of the uptake of 
IONPs seem to be mediated by an unknown mechanism as only 60% of the 
uptake into microglia and 50% into astrocytes could be inhibited by 
blocking CME and MP. Therefore, in both cell types about half of the IONP 
uptake appears to be mediated by the same pathways. The mechanisms 
resposible for the remaining part of the uptake remain to be identified in 
further studies.  
3.3 CONSEQUENCES OF AN EXPOSURE OF THE BRAIN TO IRON OXIDE AND 
SILVER NANOPARTICLES 
IONPs and AgNPs were described to reach the brain via various exposure 
routes (table 1.1). However, the impact that NPs have on the brain strongly 
depends on the type of NPs and the state, i.e. healthy or diseased, the brain is 
in. NPs that cross the BBB without eliciting any inflammation hardly have an 
influence on healthy brain regions. IONPs, for example, pass the intact BBB 
after peripheral application (Wang et al. 2010) and do not lead to an activation 
of brain cells in vitro (chapter 2.3, Raju et al. 2011) or in vivo (Alison et al. 
2010, Raju et al. 2011). The efficient accumulation of IONPs by astrocytes in 
vitro (chapter 1.5, table 2) suggests that IONPs are also taken up by astrocytes 
in vivo. As this cell type covers the brain vasculature almost completely 
(Mathiisen et al. 2010, Parpura et al. 2012), astrocytes would be the first cells 
to encounter the NPs that have passed the BBB before microglia come in 
contact to those NPs. However, data from in vivo studies indicate, that in 
healthy brain regions almost no accumulation of IONPs is found (Alison et al. 
2010).  
In state of disease or inflammation however, where an immune reaction is 
triggered, microglia are activated and accumulate high amounts of NPs (table 
1.1) which have passed the astrocytes. In case of IONPs this phenomenon has 
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been used for outlining tumour margins or visualization of inflammed brain 
regions (Fleige et al. 2001, Rausch et al. 2002, Trehin et al. 2006, Alison et al. 
2010, Oude Engberink et al. 2010, Wang et al. 2011a, Wang et al. 2011b). 
Other NPs such as AgNPs enter the brain by causing inflammation or 
disruption of the BBB themselves, which has been shown in vivo (Tang et al. 
2008, Tang et al. 2009, Sharma et al. 2010a, Sharma and Sharma 2012) and 
in vitro (Tang et al. 2010) and an accumulation of those NPs in brain can be 
expected as well.   
The effects of such an NP invasion into the brain on the cellular metabolism in 
vivo only recently became a matter of research and are controversially 
discussed. Increased levels of H2O2 as well as reduced GSH contents have 
been detected after 7 days of intranasal application of IONPs in rats indicating 
that the brains suffered from oxidative stress, although no acute toxicity was 
observed (Wu et al. 2013). Upon oral administration of AgNPs to rats over 
28 days the concentrations of neurotransmitters like dopamine were described 
to be altered in brain homogenates (Hadrup et al. 2012). In addition, 14 days 
of nasal administration of AgNPs led to an impaired synaptic plasticity as well 
as enhanced levels of ROS in rat hippocampus (Liu et al. 2012a) hinting 
towards NP-mediated oxidative stress. Dziendzikowska and co-workers, 
however, could not detect any adverse effects in rat brain in vivo after a bolus 
injection of AgNPs, but suggested impairments on the cellular level 
(Dziendzikowska et al. 2012). In a study by Genter et al. (2012), the levels of 
GSH in mouse brain were not altered upon a sinlge intranasal instillation of 
AgNPs compared to controls. Thus, for both types of NPs adverse effects have 
been described in rats after repeated administration of NPs with oxidative 
stress as the most prominent endpoint. A single application of NPs, however, 
appears to be not sufficient to trigger effects that are connected with oxidative 
stress.  
The involvement of the different brain cell-types in the observed effects has not 
been shown in vivo so far. It can only be assumed based on the known 
functions of the individual cells-types and the in vitro data available. The first 
cells that encounter NP which invade diseased or inflamed brain regions are 
believed to be astrocytes and microglia (see chapter 1). Astrocytes efficiently 
accumlated large amounts of NPs in vitro and increased their capacity for 
storage of potentially toxic NP-derived metal ions (chapter 1.5, chapter 2.1, 
chapter 2.2). Therefore, this cell-type is considered to protect the brain from 
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adverse effects of NPs or NP-derived metal ions. Microglia are known to 
accumulate NPs in vitro even faster than astrocytes, but their capacity to 
tolerate high levels of NPs is rather small compared to that of astrocytes as 
mentioned above. Usually, the big advantage of microglia is their ability to 
accumulate and degrade debris or material that is not supposed to be in the 
brain like pathogens or xenobiotics rather fast and efficient and therewith 
clear potentially harmful compounds from the brain (Aloisi 2001). Regarding 
NPs, this ability may become a disadvantage, as the degradation products of 
IONPs or AgNPs are low molecular metal ions that display a severe risk for the 
cells as they are likely to be much more toxic than the original particles (figure 
3.1). 
The highly efficient uptake and degradation of NP by microglia may therefore 
increase the possible threat to the brain due to a faster release of metal ions. 
The major part of the protection of the brain from NP-derived damage seems to 
be provided by astrocytes which trigger protein regulation and increase their 
storage capacities to safely store NPs or, in case of metal-containing NPs, also 
NP-derived ions. 
3.4 FUTURE PERSPECTIVES 
In this thesis the effects of AgNPs on cultured astrocytes and the effects of 
fluorescently labelled IONPs on cultured microglia have been investigated in 
vitro. However, some important aspects have not been addressed so far.  
AgNPs mostly are utilized due to their antimicrobial properties (Chen and 
Schluesener 2008, Dastjerdi and Montazer 2010) which are believed to depend 
on the release of Ag+ (Xiu et al. 2012). This is as much an advantage as it 
bears a risk to consumers who are exposed to those NPs. Unintended release 
of Ag+ from AgNPs might cause severe problems, as Ag+ is toxic to many cells 
types already in low concentrations (figure 3.1). Purposed release of Ag+ only in 
locally defined regions, however, would allow for example a delivery of a potent 
antimicrobial agent, i.e. Ag+, to the intended sites of action. 
Designing such tailor made particles for an application with minimized risks to 
consumers requires not only understanding the influence of the particle 
properties like size or coating on the release rates of Ag+ (Chernousova and 
Epple 2013) but also on the accumulation of those particles in cells or 
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organisms (Lankveld et al. 2010, Powers et al. 2010a). Additionally, knowledge 
on toxicity of AgNPs themselves and the ability and capacity of cells to degrade 
and metabolize AgNPs is essential to design AgNPs that display a minimal risk 
together with maximal antimicrobial properties. As AgNPs were shown to 
damage the BBB (Tang et al. 2008, Sharma et al. 2010a, Sharma et al. 2010b, 
Tang et al. 2010), a special focus should be put to the effects of AgNPs on 
brain cells where more basic research is required to understand the effects of 
AgNPs on the brain.  
This thesis provides some new insights in the handling of AgNPs by astrocytes 
describing the uptake and potential storage of AgNPs as well as their influence 
on the cell metabolism. Endocytotic uptake of AgNPs into astrocytes has been 
shown by the means of inhibition of the individual endocytotic pathways and a 
lysosomal degradation was proposed. The localization of AgNPs in vesicular 
structures was also shown by others using TEM imaging (Haase et al. 2012). 
To confirm the proposed lysosomal degradation, fluorescently labelled AgNPs 
could be used to follow their intracellular localization together with the 
application of lysotracker (Neun and Stern 2011). This would show whether 
the particles are indeed taken up into vesicles that undergo lysosomal 
degradation. Due to the low pH in lysosomes a slow release of low molecular 
silver from AgNPs in brain cells has been considered to lead to upregulation of 
storage and stress proteins like MTs (chapter 2.2) and HO-1 (Haase et al. 
2012), which protect the cells from Ag+-derived damage.  
To visualize the release of Ag+ in the cells and to confirm the causative role of 
the released ions in the induction of protein regulation, fluorescent indicators 
based on boron-dipyrromethene (BODIPY) could be applied, whose 
fluorescence is described to be enhanced or shifted upon binding to low 
molecular silver (Coskun and Akkaya 2005, Kim et al. 2008, Boens et al. 
2012). BODIPY is a molecule frequently used for imaging in live cells (Beatty et 
al. 2011, Lee et al. 2011, Qu et al. 2012, Kim et al. 2013), therefore it seems 
suitable to test the described silver-chelation capacity of BODIPY 63 and 98, 
respectively (Coskun and Akkaya 2005, Kim et al. 2008) in brain cell cultures.  
To elucidate the impact of a safe storage of AgNP-derived Ag+ in proteins like 
MTs on survival and metabolism of astrocytes, the effects of AgNPs could be 
investigated in astrocyte cultures derived from MT-deficient animals in 
comparison to wild-type animals (Yao et al. 2000). MTs and HO-1, which both 
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have been reported to be upregulated as reaction of brain cells to the presence 
of AgNPs in different studies (chapter 2.2, Haase et al. 2012), should be 
investigated in the same samples of AgNP-treated cells. The time frame after 
which the individual proteins are upregulated upon AgNP-treatment appears 
to differ, as HO-1 was already upregulated after 8 to 12 h (Haase et al. 2012), 
whereas MT-upregulation increased from 1 to 7 days (chapter 2.2). The 
monitoring of those proteins in the same setup would allow an investigation of 
a possible interplay of MT and HO-1 during the protective response on NP 
exposure in the brain. 
In addition, similar studies on AgNP uptake as those described for astrocytes 
should be performed on the other brain cell types. So far only for neurons in 
culture or in brain slices (Liu et al. 2009, Liu et al. 2011, Haase et al. 2012, 
Liu et al. 2012b) as well as for cell lines (Powers et al. 2010a, AshaRani et al. 
2012, Hadrup et al. 2012) some information is available on the effects of 
AgNPs. Also in vivo the current data is insufficient and the published results 
are even contradictory (Genter et al. 2012, Hadrup et al. 2012, Liu et al. 
2012a, Dziendzikowska et al. 2012). To investigate, which type of brain cell is 
involved in the response to AgNPs, in vitro and in vivo studies should be 
carried out with the same particle type. To enable visualization of the particles 
within the cells or in the tissue, fluorescent AgNPs could be applied. This 
would also allow a co-localization of AgNPs with markers for storage proteins 
like MTs, for cell organelles like lysosomes or for the different cell types in 
brain. 
 
IONPs are already licensed as diagnostic tool in medicine (Soenen and De 
Cuyper 2010). They serve as contrast agent in MRI for the use in liver and 
spleen (Reimer and Vosshenrich 2004, Matuszewski et al. 2007) but are also 
considered for a use in brain (Weinstein et al. 2010, Xie et al. 2011). Many 
studies describe the effects of an application of IONPs to the brain in vivo 
focussing only on their use as MRI contrast agent for labelling of cells 
(reviewed in Weinstein et al. 2010, Deddens et al. 2012). Upon exposure to 
IONPs, a decrease in the number of intact neurons as well as induced 
microglial activation have been described (Wang et al. 2011b). Data on the 
effects of an exposure of the brain to IONPs on the cell metabolism in vivo are 
very limited. Wu et al. (2013) describe increased H2O2 levels and a reduced 
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GSH content in brain homogenates 7 days after intranasal application but the 
contribution of the single cell-types to the observed alterations remain to be 
elucidated. Several studies investigated the effects of an IONP exposure to 
brain cells in vitro (table 1.1, chapter 1.5, table 2). As microglial cells were 
shown to accumulate IONPs very efficiently in vivo, a special focus needs to be 
put on those cells also in in vitro studies. Most of the information available 
results from studies on microglial cell lines (table 1.1). Only little is known on 
the handling of IONPs by primary or secondary microglial cultures (Fleige et al. 
2001, Pickard and Chari 2010b).  
This thesis provides new insights into the effects of an exposure of primary 
microglial cells to fluorescent IONPs. As microglia are known to efficiently 
degrade iron-containing magnetic particles (Jenkins et al. 2013), the fate of the 
internalized BP-DMSA coated IONPs should be investigated in more detail. 
Such studies would require elongation of the incubation times as for example 
changes in cytokine expression are only described in microglial cells several 
hours after the loading of the cells with NPs (Hutter et al. 2010, Shin et al. 
2010). However, the incubation of microglia with fluorescent IONPs utilized in 
this thesis was shown to result in a loss of cell viability already after 3 to 
6 hours. To overcome the described experimental limitations regarding 
incubation times and IONP concentrations, the cause of the observed loss in 
cell viability should be investigated in more detail. Microglia have been 
described to accumulate NPs to an extent that cannot be tolerated by the cells 
and that leads to swelling of the cells and subsequent cell death (Fleige et al. 
2001). But whether this is triggered by the quantity of internalized NPs or the 
release of high amounts of low molecular iron due to the fast and efficient 
degradation of the particles remains to be elucidated.  
If the released iron is causative for the observed cell loss after longer 
incubation periods, the use of membrane permeable iron chelators such as 
1,10-phenanthroline or 2,2´-dipyridyl (Hohnholt et al. 2010a) could allow a 
monitoring of viable cells and an intracellular metabolization of NPs over time 
as no low molecular iron-related toxicity due to degradation of the particles 
should occur. TEM images could give more information on the electron dense 
material within the lysosomes, comparable to studies with 10-times larger iron 
containing magnetic particles where the high capacity of microglial cells to 
degrade magnetic particles and a condensation of iron in vesicular structures 
have recently been shown (Pickard and Chari 2010b, Jenkins et al. 2013). If 
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the number of NPs taken up by the cells is the limiting factor, alternative 
experimental conditions have to be found to sufficiently load the cells with NPs 
without the described over-accumulation. This could be approached by 
lowering the concentrations of NPs and applying these only for a short loading 
phase with a subsequent removal of NP excess in the incubation medium. 
Culturing IONP-loaded microglial cells over several hours would allow 
monitoring of a possible increase in mRNA and upregulation of iron transport 
and storage proteins as depicted in figure 1.2 by reverse transcription PCR 
and Western blot analysis. IONP-related effects on the production and release 
of cytokines, ROS and NO should also be studied in such a setup as this has 
been described in microglial cells for other NPs (Long 2006, Hutter et al. 2010, 
Lalancette-Hébert et al. 2010, Shin et al. 2010) as well as for IONPs (Wang et 
al. 2011b). 
Irrespective of the type of nanoparticle addressed, it is essential to study the 
effects of NPs in brain and to combine in vitro and in vivo approaches utilizing 
the same type of NPs to understand the consequences that those NPs have on 
the individual cell types as well as on the interplay of NP-exposed brain cells. 
This knowledge may help to develop new approaches for the design of safe NP-
based consumer and medical products.?
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